

Rethinking Personalized **Fertility Preservation** and Cancer Survivors - Opening a New Frontier -

ISFP2024 The 8th World Congress of the International Society ΤΟΚΥΟ

for Fertility Preservation

🚥 November 15-17, 2024 | Tokyo, Japan

Î Î Î

I

PROGRAM BOOK



Fertility Preservation Saving tissue for the future



World Standard Ovarian Tissue Vitrification



Kitazato Corporation

HEADQUATER : 100-10 Yanagishima, Fuji, Shizuoka 416-0932 JAPAN TOKYO : 1-1-8 Shibadaimon, Minato-ku, Tokyo 105-0012 JAPAN Copyright C Kitazato Corporation All Rights Reserved.



This product is not a 'drug' or 'medical device' as defined by the Pharmaceutical Affairs Law. It is not intended for diagnostic or therapeutic use in humans or animals.

TIMETABLE

Workshops A and B (conducted simultaneously) are not included in the general congress registration fees and require separate registration.

Frida	y, November 15 <day 1=""></day>	産 産婦人	科領域講習 🕺	泌尿器科領域講習
Time	Room 1	Room 2	Worl	kshop
9:00-	9:00-9:15 Opening Ceremony			
9.00	Break		9:10-12:40	
10:00-	9:20-11:00 Session 1 ASFP Session with ISFP Case Discussion	9:20-11:10 Session 2 IVM	Workshop A Ovarian Tissue Vitrification	10:10-12:40 Workshop
11:00-	Coffee Break			В
12:00-	11:20-12:40 Session 3 Ovarian Tissue Transportation	Break 11:20-12:40 Session 4 KSFP Session	KITAZATO.	IVM and Oocyte Vitrification
13:00-	Coffee 13:00-14:00 Luncheon Seminar 1	Break 13:00-14:00 Luncheon Seminar 2		
14:00-	KITAZATO. Bre	株式会社 CGI		
15:00-	14:10-15:10 Afternoon Seminar Blood Cancer Imovation all of the patients Dimer CHUGAI PHARMACEUTICAL CO, LTD. Comp Mache Energy	14:10-15:10	Workshop A Ovarian	14:20-16:50 Workshop B IVM and
16:00-	15:20-16:40 Session 6 Ovarian Tissue Transplantaion	15:20-16:40 Session 7 CSFP Session	Tissue Vitrification	Oocyte Vitrification
17:00-	Coffee Break			KITAZATO.
	17:00-18:00 Session 8	17:00-18:20 Session 9	KITA 7/ ATO.	
18:00-	Ovarian Protection	Oral Session 1]
			1	

TIMETABLE

Saturday, November 16 < Day 2>

泌 泌尿器科領域講習

Simultaneous Translation (Japanese – English)

Time	Room 1	Room 2	Poster
8:00-	8:00-9:00 Honorary Lecture 1 Honorary Lecture 2 President's Lecture	Appreciation for Retired Board Members	Poster Mounting
9:00-	9:10-10:30 🐱 🕟	eak 9:10-10:30	9:00-17:30
10:00-	Session 10 New Technology 1	Session 11 Benign Disease 1 Gynecological Conditions and Uterus	
	Coffee	: Break	
11:00-	10:50-12:10	10.30-12.10	
	Session 12 JSFP Session	Session 13 Nurse Session	
12:00-		Nuise dession	
		Break	
13:00-	12:30-13:50 Luncheon Seminar 3 Cancer Survivorship	12:30-13:30 Luncheon Seminar 4 VITROLIFE GROUP Include to Monotoriation Ignoregia Weeking	Poster Group A
14:00-	Break 14:00-15:50	Break 13:40-15:40 Session 15	
15:00-	Session 14 Clinical Practice	Oral Session 2 Best Oral Presentation Finalists	
16:00-	Break	Coffee Break	
	16:00-17:20 Session 16	16:00-17:20 Session 17	
17:00-	Oral Session 3	Oral Session 4	
18:00-			Poster Dismantling

TIMETABLE

Sunday, November 17 < Day 3>

泌 泌尿器科領域講習

Simultaneous Translation (Japanese – English)

Time	Room 1	Room 2	Poster
8:00-	8:00-8:40		
	Special Lecture		Poster Mounting
	Coffee	Break	i oster mounting
9:00-	9:00-10:20	9:00-10:20	9:00-14:10
	Session 18	Session 19	
10:00-	Artificial Ovary	ASFP Session Fertility Preservation in Developing Countries	
	Bre		
11:00-	10:30-11:30 Bession 20 Testicular Tissue	10:30-11:30 Session 21	Bester
	Cryopreservation	Benign Disease 2 Turner Syndrome	Poster Group B
	Coffee Break		Gloup B
12:00-	11:50-12:50 Luncheon Seminar 5	11:50 ~ 12:50 Luncheon Seminar 6 Breast Cancer	
		KONDERSE MSD要要 Noventhor For Life MSD M	
13:00-	Bre 13:00-14:00	ak 13:00-14:00	
	Session 22	Session 23	
	Oral Session 5	Oral Session 6	
14:00-	Bre		
	14:10-15:30 ••••••••••••••••••••••••••••••••••••	14:10-15:30 Session 25	Poster Dismantling
15:00-	Ovarian Tissue	New Technology 2	
15.00-	Cryopreservation		
	15:30-16:00		
16:00-	Closing Ceremony		
17:00-			
17.00-			

WELCOME NOTE

Dear friends and colleagues,

The ISFP was founded in September 2007 (Boston, MA) by Drs. Jacques Donnez, Samuel Kim, Pasquale Patrizio, Roger Gosden and Tommaso Falcone, pioneers in the field of fertility preservation to promote research and clinical practice. The first World Congress of the ISFP (International Society for Fertility Preservation) was held in Brussels under the presidency of Dr. Jacques Donnez (the 1st president) in 2009. Since then, this interdisciplinary area has been developed through the workings of the ISFP.

We are honored to host the 8th World Congress of the ISFP in Tokyo in 2024. At ISFP 2024 in Tokyo, I believe that the congress will be packed with the latest information in this field for doctors as well as other medical professionals. At the ISFP 2024 in Tokyo, there will be in-depth discussions on various topics in many areas during the three-day sessions. In particular, this year's congress has increased the number of sessions for general presentations, which will be beneficial to young researchers who will lead the next generation in this field. In addition, we have included sessions not only on basic research but also on areas of social importance. We also received a large number of abstracts from the Asian Society for Fertility Preservation (ASFP), which we established with our Asian colleagues in 2015. I would like to express my sincere gratitude to my colleagues in Asia. I also would like to express my deepest gratitude to Dr. Debra Gook, ISFP Vice President, Dr. Marie-Madeleine Dolmans, Secretary, Dr. Tommaso Falcone, Treasurer, Dr. Michael von Wolff and Scientific Program Committee members. I would also like to thank Dr. Jacques Donnez and Dr. Pasquale Patrizio for their long-term guidance to me in this field. Finally, I would like to express my sincere gratitude to my mentor in this field, Dr. Samuel Kim, whom I respect very much.

The main theme of the Congress will be "Rethinking Personalized Fertility Preservation and Cancer Survivors – Opening a New Frontier". Since the establishment of the ISFP, the pace of development in the field of fertility preservation has never been faster, and both cancer treatment outcomes and reproductive outcomes in this area have been reported in large numbers in recent years in the United States and Europe. However, there continues to be a growing need to further improve survivorship for childhood and AYA cancer patients who are seeking long-term survival.

I hope that this congress in Tokyo will provide an opportunity for members of the ISFP to explore the direction we should take in the future to further improve the survivorship of childhood and AYA cancer patients to ensure their long-term survival.

Sincerely yours,



2 77 Nao Suguks

Nao Suzuki, M.D., Ph.D. The 8th President of the ISFP Congress Chairperson of the 8th World Congress of the ISFP Professor and Chair, Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan Deputy Director, St. Marianna University Hospital, Kawasaki, Japan

ISFP BOARD OF DIRECTORS

President

Nao Suzuki, Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kanagawa, Japan

Vice President Debra A Gook, Reproductive Services, Royal Women's Hospital, Australia

Secretary, Immediate Past President Marie-Madeleine Dolmans, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Treasurer

Tommaso Falcone, Cleveland Clinic, USA

Claus Yding Andersen, The Fertility Clinic, University Hospital Herlev, Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

Nalini Kaul Mahajan, Mother & Child Hospital, New Delhi, India

Dror Meirow, Past President, Fertility Preservation Center, Sheba Medical Center, Tel Aviv University, Israel

Pasquale Patrizio, Past President, Division Reproductive Endocrinology and Infertility, Dept. Obstetrics/Gynecology and Reproductive Sciences, University of Miami, Miller School of Medicine, USA

Antonio Pellicer, Ob/Gyn University of Valencia Co- President IVIRMA Global Co-Editorin-Chief Fertility & Sterility

Catherine J Poirot, Department of Hematology, Fertility Preservation, Saint Louis Hospital, Paris

Kenny A Rodriguez-Wallberg, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Zev Rosenwaks, Weill Cornell Medicine-the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, USA

Glenn Schattman, The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Medical College of Cornell University, USA

Chii-Ruey Tzeng, Taipei Fertility Center, Taiwan

Michael von Wolff, University Womens Hospital, Bern, Switzerland

Hamish Wallace, Department of Paediatric Haematology and Oncology, Royal Hospital for Children and Young People and University of Edinburgh, Edinburgh, United Kingdom

Terri Woodard, Baylor College of Medicine, USA

Literature Review & Newsletter (Non-Voting Member)

Luciana Cacciottola, Gynecology Rresearch Unit, UC Louvain, Belgium

Honorary Lifetime Member

Gosden Roger, The College of William & Mary Williamsburg, Virginia, USA

Outi Hovatta, Karolinska Institutet Karolinska University Hospital Huddinge, Stockholm, Sweden

Pedro Barri, Departamento de Obstetricia, Ginecología y Reproducción Institut Universitari Dexeus, Barcelona, Spain

Jacques Donnez, UCLouvain, Brussels, Belgium

Samuel Kim, California Fertility Clinic, USA

Peter Nagy, Reproductive Biology Associates, Atlanta, USA

Scientific Program Committee

Debra Gook, Australia Marie-Madeleine Dolmans, Belgium Claus Yding Andersen, Denmark Michael von Wolff, Switzerland Nalini Kaul Mahajan, India Pasquale Patrizio, USA Glenn Schattman, USA

The ISFP 2024 Tokyo Secretariat

Yodo Sugishita (Secretary General)

Yuki Suzuki

Kentaro Nakamura


Hideyuki lwahata

Natsuko Harizuka

Membres of Department of Obstetrics and Gynecology, St. Marianna University School of Medicine



Mohd Faizal Ahmad Malaysia



Lauren Alesi Australia



Claus Yding Andersen Denmark



Erica J. Behnke USA



Jana Bender-Liebenthron Germany



Luciana Cacciottola Belgium



Jesús Cadenas Denmark



Ri-Cheng Chian China



Young Sik Choi Korea



Richard Choy Hong Kong



Michel De Vos Belgium





Sanaz Derech-Haim Marie-Madeleine Dolmans Israel Belgium

Jacques Donnez Belgium



Tommaso Falcone USA



Olivia Jaworek Frias USA



Tatsuro Furui Japan



Debra Gook Australia



Yichun Guan China



Miyuki Harada Japan



Shu Hashimoto Japan



Katsuhiko Hayashi Japan




Karla Hutt Australia



Kyung Hwang Korea



Arby Jane Igualada Phillippines



Tomoaki Ikeda Japan



Tomoko Inoue Japan



Bunpei Ishizuka Japan



Malene Johannsen Denmark



Hiroaki Kajiyama Japan



Yoshinobu Kanda Japan



Oren Kashi Israel



Yukiko Katagiri Japan



Jihyang Kim Korea



Samuel Kim USA



Anastasia Kirillova Australia



Koichi Kyono Japan



Monica Laronda USA



Jung Ryeol Lee Korea



Chun-l Lee Taiwan



Da Li China



Wen Li China



Nalini Kaul Mahajan India



Eileen Manalo Phillippines



Kathryn McFadden Australia



Dror Meirow Israel



Xiangkai Meng China



Yoshiharu Morimoto Japan



Jennifer Mueller USA



Virgilio JR B. Novero Philippines



Takehiko Ogawa Japan



Shinji Ohno Japan



Hiroshi Okada Japan



Kutluk Oktay USA



Ozgur Oktem Turkey



Masanori Ono Japan



Kyle Orwig USA



Yutaka Osuga Japan



Emma Ouni France



Pasquale Patrizio USA



Catherine Poirot Kenny Rodriguez-Wallberg France



Sweden



Zev Rosenwaks USA



Nicole Sänger Germany



Glenn Schattman USA




Chikako Shimizu Japan



Sherman Silber USA



Petra Stute Switzerland



Yodo Sugishita Japan



Chang Suk Suh Korea



Nao Suzuki Japan



Yasushi Takai Japan



Chii-Ruey Tzeng Taiwan



Michael von Wolff Switzerland



Hamish Wallace UK



Chie Watanabe Japan



Budi Wiweko Indonesia



Terri Woodard USA

12



Kai Yamasaki Japan

PAST CONGRESSES

Congress	Year	City, Country	President
1st	2009	Brussels, Belgium	Jacques Donnez
2nd	2011	Miami Beach, USA	Samuel Kim
3rd	2013	Valencia, Spain	Pedro Barri
4th	2015	Shanghai, China	Pasquale Patrizio
5th	2017	Vienna, Austria	Dror Meirow
6th	2019	New York, USA	Tommaso Falcone
7th	2022	Brussels, Belgium	Marie-Madeleine Dolmans
8th	2024	Tokyo, Japan	Nao Suzuki

WORKSHOPS

Ovarian Tissue Vitrification

Workshop A 9:10-12:40 / 14:10-17:40, Friday, November 15, 2024 Instructors: **Nao Suzuki**, Japan **Yodo Sugishita**, Japan **Yuki Suzuki-Takahashi**, Japan **Sayako Furuyama**, Japan

IVM and Oocyte Vitrification Workshop B 10:10-12:40 / 14:20-16:50, Friday, November 15, 2024 Instructors: Nao Suzuki, Japan Chiemi Toyama, Japan Honami Kobayashi, Japan Yumiko Nakano, Japan

KITAZATO.

Industry-supported Seminar by Kitazato Corporation

ISFP sincerely thanks Kitazato Corporation, Nikon Solutions Co., Ltd., and Eda Shokai Inc. for providing equipment for the Ovarian Tissue Vitrification Workshop and the IVM and Oocyte Vitrification Workshop.

FRIDAY, NOVEMBER 15, 2024		
Room 1		
9:00- 9:15	Opening Ceremony Opening Remarks: Nao Suzuki , Japan	
9:15- 9:20	Break	
9:20-11:00	Session 1 ASFP Session with ISFP: Case Discussion Chairs: Arby Jane Roque Igualada , Philipines; Mohd Faizal F Ahmad , Malaysia Discussants: Kenny A Rodriguez-Wallberg , Sweden; Marie-Madeleine Dolmans , Belgium	
9:20- 9:30	Case 1: Fertility preservation in breast cancer Case Presenter: Evelyn Wong , Hong Kong	
9:30- 9:50	Discussion for Case 1 Discussants: Jennifer K Y Ko , Hong Kong; Nalini Kaul Mahajan , India	
9:50-10:00	Case 2: Fertility preservation in a patient with endometrial cancer Case Presenter: Jasneet Kaur , India	
10:00-10:20	Discussion for Case 2 Discussants: Madhuri M Patil , India; Budi Wiweko , Indonesia	
10:20-10:30	Case 3: Fertility preservation in endometriosis Case Presenter: Budi Wiweko , Indonesia	
10:30-10:50	Discussion for Case 3 Discussants: Jung Ryeol Lee , Korea; Chii-Ruey Tzeng , Taiwan	
11:00-11:20	Coffee Break	
11:20-12:40	Session 3 Ovarian Tissue Transportation Chairs: Catherine J Poirot , France; Koichi Kyono , Japan	
11:20-11:40	Ovarian tissue transportation Claus Yding Andersen, Denmark	
11:40-12:00	Overnight transport of ovarian tissue for cryopreservation in a central cryobank: a feasible option for standardised and high-quality medical freezing Jana Bender-Liebenthron , Germany	
12:00-12:20	Safe and secure ovarian tissue transportation in the Human Ovarian-tissue Preservation Enterprise (HOPE) Koichi Kyono , Japan	

產產婦人科領域講習

	FRIDAY, NOVEMBER 15, 2024
Room 1	
12:20-12:40	General Discussion
12:40-13:00	Break
13:00-14:00	Luncheon Seminar 1 Chairs: Nao Suzuki , Japan Industry-supported Seminar by Kitazato Corporation KITAZATO
13:00-13:50	Improving ovarian transplantation and in vitro primordial follicle growth outcomes with cryopreserved Tissue Kutluk Oktay , USA
13:50-14:00	Question-and-answer Session
14:00-14:10	Break
14:10-15:10	Afternoon Seminar 1 Blood Cancer Chairs: Yoshinobu Kanda , Japan; Dror Meirow , Israel Industry-supported Seminar by CHUGAI PHARMACEUTICAL CO. LTD
14:10-14:30	Expert Lecture 1 Preservation of fertility in patients with hematological malignancies Yoshinobu Kanda , Japan
14:30-14:50	Expert Lecture 2 Safe and successful ovarian transplantations post LEUKEMIA after combined various MRD excluding tests future novel options for contaminated tissue Dror Meirow , Israel
14:50-15:10	Question-and-answer Session
15:10-15:20	Break
15:20-16:40	Session 6 Ovarian Tissue Transplantation Chairs: Claus Yding Andersen , Denmark; Dror Meirow , Israel
15:20-15:40	Lessons learned from European experience in ovarian tissue transplantation Catherine J Poirot , France
15:40-16:00	Effectiveness of ovarian tissue transplantation and available experimental strategies for future improvement Luciana Cacciottola , Belgium

產產婦人科領域講習

FRIDAY, NOVEMBER 15, 2024		
Room 1		
16:00-16:20	Addressing unmet needs in ovarian tissue cryopreservation and transplantation Jung Ryeol Lee , Korea	
16:20-16:40	General Discussion	
16:40-17:00	Coffee Break Relax and enjoy some coffee, wine and beer before the final session of the afternoon.	
17:00-18:00	Session 8 Ovarian Protection Chairs: Pasquale Patrizio , USA; Michael von Wolff , Switzerland	
17:00-17:20	Activation or Apoptosis: Combined suppression of intrinsic and extrinsic follicle activation pathways completely prevents cyclophosphamide-induced follicle loss, while DNA damage does not end in oocyte apoptosis Oren Kashi , Israel	
17:20-17:40	Estimating the effectiveness of GnRHa drugs for ovarian protection during cancer treatment through a RCT including adolescents and adults – Why such a study is needed Kenny A Rodriguez-Wallberg , Sweden	
17:40-18:00	General Discussion	

	FRIDAY, NOVEMBER 15, 2024
Room 2	
9:20-11:10	Session 2
	IVM
	Chairs: Glenn L. Schattman, USA; Ri-Cheng Chian, China
9:20- 9:40	Understanding of the regulatory mechanisms in human IVM in connection with
	OTC
	Jesús Cadenas, Denmark
9:40-10:00	Recent data on IVM and its application in oncofertility
	Michel De Vos, Belgium
10:00-10:20	Pre-IVF incubation system improves the quality of eggs for fertility preservation
	Ri-Cheng Chian, China
10:20-10:40	Effect of local environment on primordial follicle activation
	Sanaz Dereh Haim Tzfanya, Israel
10:40-11:10	General Discussion
11:10-11:20	Coffee Break
11:20-12:40	Session 4
	KSFP Session
	Chairs: Chang Suk Suh, Korea; Kyungjoo Hwang, Korea
11:20-11:31	Efficacy of cyst aspiration following dienogest medication of
	endometrioma for preserving ovarian reserve
	Haeun Jung, Korea
11:31-11:42	Single-cell RNA sequencing reveals the cell-type-specific mechanisms of
	ovarian regeneration in rat POI models treated with platelet-rich plasma (PRP)
	Jungwoo Shin, Korea
11:42-11:53	Effects of PD-1 inhibitor and/or cyclophosphamide on ovarian reserve in
	murine model
	Inha Lee, Korea
11:53-12:04	Long-term outcomes of fertility preservation counselling in women of
	reproductive age with cancer
	Euna Choi, Korea
12:04-12:15	Effect of autologous bone marrow derived stem cells and platelet rich plasma
	therapy after hysteroscopy for severe Asherman's syndrome
	Hye Kyung Yoon, Korea
12:15-12:26	Development and alpha testing of decision aid for decision-making of fertility
	preservation considering cancer patient's personal values
	Sokbom Kang, Korea

產產婦人科領域講習

<mark>泌</mark>泌尿器科領域講習

	FRIDAY, NOVEMBER 15, 2024
Room 2	
12:26-12:37	Effect of long-term humanin treatment on preventing age-related decline in oocyte quality Hyewon Min , Korea
12:40-13:00	Break
13:00-14:00	Luncheon Seminar 2 Chair: Seido Takae , Japan Industry-supported Seminar by CGI K.K. 株式会社 CG
13:00-14:00	Introduction to CAP reproduction laboratory accreditation program Erica J Behnke , USA
14:00-14:10	Break
14:10-15:10	Session 5 🛛 🛛 🕅 PGT Chairs: Zev Rosenwaks , USA; Chii-Ruey Tzeng , Taiwan
14:10-14:30	PGT-A testing in oncofertility: benefit or harm? Glenn L. Schattman, USA
14:30-14:50	Importance of genetics in oncofertility: lesson learn from PGT Richard KW Choy, Hong Kong
14:50-15:10	General Discussion
15:10-15:20	Break
15:20-16:40	Session 7 CSFP Session Chairs: Wen Li , China; Da Li , China
15:20-15:31	Considerations and thoughts of patients undergoing medical fertility preservation a new perspective on promoting fertility preservation Jing Yue , China
15:31-15:42	Follicular growth after cryopreservation/thawing and activation of children ovarian tissue Xinyu Zhang, China
15:42-15:53	Clinical outcomes of intracytoplasmic sperm injection with fresh or cryopreserved ejaculated or surgically retrieved sperm Chunyi Li , China
15:53-16:04	Research of application and mechanism of hyperbaric oxygen therapy on ovarian tissue transplantation Ningxia Sun , China

	FRIDAY, NOVEMBER 15, 2024
Room 2	
16:04-16:15	Ultra-rapid cooling and warming enhanced low-CPA vitrification of ovarian
	tissues
	Gang Zhao, China
16:15-16:26	The impact of letrozole on the ovulation induction process and pregnancy
	outcome in fertility preservation patients
	Hui Min Tao, China
16:26-16:37	Fertility preservation in young breast cancer patients: A national survey on
	knowledge, attitudes, and practices among breast surgical healthcare
	providers in China
	Xiaoling Yuan, China
16:40-17:00	Coffee Break
	Relax and enjoy some coffee, wine and beer before the final session of the afternoon.
17:00-18:20	Session 9
	Oral Session 1
	Chairs: Ozgur Oktem, Turkey; Masanori Ono, Japan
17:00-17:10	Progress in ovarian tissue cryopreservation at the fertility preservation center
	of obstetrics and gynecology hospital of fudan university
	Ying Zhang, China
17:10-17:20	An update of graft function and reproductive outcomes from ovarian tissue
	cryopreservation and graft: Lessons from 46 women
	Louie Ye, Australia
17:20-17:30	Elucidating Ki-67, Caspase-3 and Hematoxylin & Eosin (H&E) in assessing the
	integrity of ovarian follicle following ovarian tissue cryopreservation via
	vitrification method among oncofertility patient in university hospital setting
47.00.47.40	Mohd Faizal F Ahmad, Malaysia
17:30-17:40	Insights into how freezing affects follicle development in human ovarian
	tissues
47 40 47 50	Nilay Kuscu, UK
17:40-17:50	Mechanism of mitochondrial targeted antioxidant MitoQ promoting
	angiogenesis after frozen-thawed ovarian tissue transplantation
17:50-18:00	Lingbo Meng, China
17:50-18:00	Nano-curcumin potentially ameliorates hormonal function and follicular counts
	following the vitrification and transplantation of rats ovarian tissue
	Satria Audi Hutama, Indonesia

	FRIDAY, NOVEMBER 15, 2024
Room 2	
18:00-18:10	Exploring the mechanism of Everolimus in inhibiting the activation of primordial
	follicles to improve the efficiency of human ovarian cortex cryopreservation
	and resuscitation-transplantation
	Yichun Guan, China
18:10-18:20	Correlations between histology type and FIGO stage ovarian malignancy with
	type of surgery in adolescence and young adult patient
	Syamel Muhammad, Indonesia

泌尿器科領域講習

	SATURDAY, NOVEMBER 16, 2024
Room 1	
8:00- 8:15	Honorary Lecture 1
	Chair: Yoshiharu Morimoto , Japan
8:00- 8:15	Ovarian transplantation: lessons from the past to the future
	Samuel Kim, USA
8:15- 8:30	Honorary Lecture 2
	Chair: Bunpei Ishizuka , Japan
8:15- 8:30	From Gosden to ovarian organoids : a long path full of success
	Jacques Donnez, Belgium
8:30- 8:45	President's Lecture
	Chair: Debra A Gook , Australia
8:30- 8:45	My 18-year journey with ovarian tissue cryopreservation – from an oncologist's
	point of view
	Nao Suzuki, Japan
8:45- 9:00	Appreciation for Retired Board Members
8:45- 9:00	Remarks from retired members
	Chii-Ruey Tzeng, Taiwan; W. Hamish Wallace, UK
9:00- 9:10	Break
9:10-10:30	Session 10 🛛 🕅
	New Technology 1
	Chairs: Debra A Gook , Australia; Pasquale Patrizio , USA
9:10- 9:30	Reconstruction of ovarian tissue incorporating germ cell lineages
	Katsuhiko Hayashi, Japan
9:30- 9:50	Advancements in in vitro spermatogenesis
	Takehiko Ogawa, Japan
9:50-10:10	Recent data on IVM and its application to oncofertility (capacitation-IVM)
	Anastasia Kirillova, Australia
10:10-10:30	General Discussion
10:30-10:50	Coffee Break
10:50-12:10	Session 12
	JSFP Session
10.50 10.50	Chairs: Yasushi Takai, Japan; Tatsuro Furui, Japan
10:50-10:52	Greetings and Introduction from JSFP
10:52-11:18	Standardization and sustainable development of onco-fertility network in
	Japan: The mission of Onco-fertility Consortium Japan
	Masahito Tachibana, Japan

	SATURDAY, NOVEMBER 16, 2024
Room 1	
11:18-11:44	The public subsidy program as a part of the Research Promotion Project led by
	the Japanese Ministry of Health, Labour and Welfare
	Miyuki Harada, Japan
11:44-12:10	A new approach to enhancing human resource development in fertility
	preservation: The JSFP model
	Masanori Ono, Japan
12:10-12:30	Break
12:30-13:50	Luncheon Seminar 3
	Cancer Survivorship
	Chairs: Michael von Wolff, Switzerland; Chikako Shimizu, Japan
	Industry-supported Seminar by Merck MCRCK
12:30-12:50	Fertility issues in cancer patients and survivors - from an oncologist's
	perspective
	Chikako Shimizu, Japan
12:50-13:10	latrogenic POI treatment options after cancer
	Petra Stute, Switzerland
13:10-13:30	Fertility preservation and infertility treatment in women with very low ovarian
	reserve
10.00.10.70	Michael von Wolff, Switzerland
13:30-13:50	General Discussion
13:50-14:00	Break
14:00-15:50	Session 14
	Clinical Practice
44.00 44.00	Chairs: Terri L Woodard, USA; Luciana Cacciottola, Belgium
14:00-14:20	Fertility preservation practices and achievements at the Henan Provincial
	Maternal and Child Health Hospital
14:20-14:40	Yichun Guan, China IVF characteristics and the molecular luteal features of random start IVF cycles
14.20-14.40	are not different from conventional cycles in cancer patients
14:40-15:00	Ozgur Oktem, Turkey Progestin-primed ovarian stimulation in oncofertility
14.40-13.00	Eileen M Manalo, Philippines
15:00-15:20	Live birth and maternity outcome in childhood and adolescent cancer survivors
15.00-15.20	under 18 years at diagnosis: a 40-year population-based cohort study
	W Hamish Wallace. UK
15:20-15:40	General Discussion
15:50-16:00	Coffee Break

SATURDAY, NOVEMBER 16, 2024	
Room 1	
16:00-17:20	Session 16
	Oral Session 3
	Chairs: Pasquale Patrizio, USA; Yasushi Takai, Japan
16:00-16:10	Transplantation of cryopreserved ovarian tissue in two patients of
	gyneacologic cancers
	Yan Ding, China
16:10-16:20	Fertility rescuing by heathy ovarian tissue graft in mouse model of
	chemotherapy-induced ovarian insufficiency
	Mahiru Kawano, Japan
16:20-16:30	Fertility preservation in a case of intravenous leiomyomatosis
	Sabhyata Gupta, India
16:30-16:40	A study of the delivery course in cases of maternal deaths from malignant
	tumors in Japan
	Shinji Katsuragi, Japan
16:40-16:50	Associations between nutrient intake and menopausal age in Korean women:
	Findings from the Korea National Health and Nutrition Examination Survey
	Miran Kim, Korea
16:50-17:00	Evaluating mitochondrial DNA copy number for predicting IVF outcomes in
	euploid blastocysts
	Jieun Ko, Korea
17:00-17:10	The relationship between nutritional status, DNA damage and metabolites in
	women with infertility in Malaysia
	Muhammad Azrai Abu, Malaysia
17:10-17:20	Macrophage infiltration and fibrosis of the ovaries in chemotherapy-induced
	ovarian insufficiency
	Gaku Yamamoto, Japan

	SATURDAY, NOVEMBER 16, 2024
Room 2	
9:10-10:30	Session 11
	Benign Disease 1: Gynecological Conditions and Uterus
	Chairs: Nalini Kaul Mahajan, India; Tommaso Falcone, USA
9:10- 9:30	Fertility preservation for the patients with uterine fibroids and adenomyosis
	Tommaso Falcone, USA
9:30- 9:50	Fertility preservation for patients with endometriosis
	Miyuki Harada, Japan
9:50-10:10	Radiotherapy exposure directly damages the uterus and causes pregnancy
	loss
	Lauren R Alesi, Australia
10:10-10:30	General Discussion
10:30-10:50	Coffee Break
10:50-12:10	Session 13
	Nurse Session
40 50 44 40	Chairs: Chie Watanabe, Japan; Olivia Jaworek Frias, USA
10:50-11:10	The role of nurses in oncofertility - current status in Japan
11:10-11:30	Chie Watanabe, Japan The role of nurses in oncofertility - current status at CCHMC/USA
11:10-11:30	-
11:30-11:50	Olivia Jaworek Frias, USA Experience of fertility preservation nurse coordinator in a large paediatric
11.30-11.50	hospital
	Kathryn McFadden, Australia
11:50-12:10	General Discussion
12:10-12:30	Break
12:30-13:30	Luncheon Seminar 4
	When It Comes to Fertility Preservation and Reproductive Genetics, What Is
	Best Practice for Patients?
	Chair Miyuki Harada Japan
	Industry-supported Seminar by Vitrolife
12:30-12:55	Talk 1
	Incorporating reproductive genetics into IVF: carrier screening, PGT-M and
	PGT-A
	Chun-I Lee, Taiwan
12:55-13:20	Talk 2
	Fertility preservation, oocyte vitrification and ovarian tissue cryopreservation
	Debra A Gook, Australia
13:20-13:30	Question-and-answer Session

	SATURDAY, NOVEMBER 16, 2024
Room 2	
13:30-13:40	Break
13:40-15:40	Session 15
	Oral Session 2: Best Oral Presentation Finalists
	Chairs: Zev Rosenwaks, USA; Tommaso Falcone, USA
13:40-13:50	Melatonin protects intact rat ovarian transplantation via the MT1/Nrf2/ARE
	pathway
	Yan Ding, China
13:50-14:00	Oocyte cryopreservation in peripubertal girls with Turner's syndrome:
	An analysis of molecular and clinical reproductive parameters
	Hesam Ghafouri Kalajahi, Turkey
14:00-14:10	Beyond the cancer: Twenty-year analysis of fertility preservation outcomes in
	young women with cancer
	Karen B Glass, Canada
14:10-14:20	Ovarian tissue cryopreservation in France: data from the GRECOT (Research
	and study group for ovarian and testicular cryopreservation)
	Jean-Christophe Pech, France
14:20-14:30	Australian Experience with a National Ovarian and Testicular tissue Transport
	and Cryopreservation Service (NOTTCS)
	Marina Demyanenko, Australia
14:30-14:40	eNOS expression in human ovarian tissues after vitrification-thawing and
	transplantation in different sizes
	Agung Dewanto, Indonesia
14:40-14:50	Inflammatory signaling is activated downstream of cyclophosphamide
	exposure and is sufficient to induce damage to mouse ovarian reserve
	Limor Man, USA
14:50-15:00	AMHR2BP for the prevention of cyclophosphamide (CX)-induced ovarian
	follicle depletion in mice
45.00.45.40	Laura Detti, USA
15:00-15:10	Fertility preservation and live birth using a gelatin-Methacryloyl-based
	bioprosthetic ovary mimicking natural ovarian function
45.40 45.00	Nanum Chung, Korea
15:10-15:20	Impact of preimplantation genetic testing in number of usable embryos
15:20-15:30	Sayaka Higo, Hong Kong Ovarian tissue after thawing: Metabolic recovery and hormonal effects in
15.20-15.30	- · ·
	angiogenesis
	Rebekka Einenkel, Germany

	SATURDAY, NOVEMBER 16, 2024
Room 2	
15:30-15:40	The first comparative study on the effectiveness of slow freezing and
	vitrification of human ovarian tissue by xenotransplantation model in vietnam
	Thi Minh Chau Le, Viet Nam
15:40-16:00	Coffee Break
16:00-17:20	Session 17
	Oral Session 4
	Chairs: Chii-Ruey Tzeng, Taiwan; Virgilio M Novero JR, Philippines
16:00-16:10	Letrozole-induced ovulation for endometrial preparation in frozen embryo
	transfer cycles for women with endometrial intraepithelial neoplasia or cancer
	Sule Yildiz, Turkey
16:10-16:20	IVM on the patients required emergent oocyte retrieval for fertility preservation
	Aisaku Fukuda, Japan
16:20-16:30	Focusing on time-lag post-in vitro maturation in oocyte tissue cryopreservation:
	A laboratory perspective
	Hiromitsu Shirasawa, Japan
16:30-16:40	Effects of prolonged cryopreservation of oocytes on fertilization and pregnancy
	outcomes: A systematic review and meta-analysis
	Jennia Michaeli, Canada
16:40-16:50	Assessing oncological safety and fertility potential in ovarian cortex
	surrounding epithelial and early-stage malignant ovarian tumors inpatients of
	reproductive age
	Luciana Cacciottola, Belgium
16:50-17:00	The oncologic and reproductive outcomes after fertility-sparing surgery in
	gynecological cancers
	Tzu-Ya Wang, Taiwan
17:00-17:10	Knowledge, attitude, and practice toward fertility preservation among young
	women with systemic autoimmune rheumatic disease facing treatment with
	gonadotoxic agents in Indonesia: A cross-sectional study
	Irene Sinta Febriana, Indonesia
17:10-17:20	Pregnancy outcomes following fertility preservation utilizing in vitro maturation
	of oocytes in cancer patients: A systematic review
	Cokorda I A Anggitaswari, Indonesia

泌尿器科領域講習

SUNDAY, NOVEMBER 17, 2024	
Room 1	
8:00- 8:40	Special Lecture
	Chair: Yutaka Osuga , Japan
8:00- 8:40	Uterine and ovarian transposition: Novel procedures to preserve fertility in
	young women with pelvic cancers
	Speaker: Jennifer Mueller, USA
8:40- 9:00	Coffee Break
9:00-10:20	Session 18
	Artificial Ovary
	Chairs: Debra A Gook, Australia; Marie-Madeleine Dolmans, Belgium
9:00- 9:20	Bioengineering an ovarian microenvironment informed by the human ovary
	biomolecular atlas
	Monica M Laronda, USA
9:20- 9:40	Importance of interactions between human theca- and granulosa cells in
	making an artificial ovary
	Malene Louise Johannsen, Denmark
9:40-10:00	Ex-vivo ovarian perfusion: a new tool in fertility preservation and beyond
	Pasquale Patrizio, USA
10:00-10:20	General Discussion
10:20-10:30	Break
10:30-11:30	Session 20 🛛 🕺
	Testicular Tissue Cryopreservation
	Chairs: Catherine J Poirot, France; Dror Meirow, Israel
10:30-10:50	Testicular tissue cryopreservation and prospects for future reproduction
	Kyle E Orwig, USA
10:50-11:10	Testicular tissue cryopreservation
	Hiroshi Okada, Japan
11:10-11:30	General Discussion
11:30-11:50	Break
11:50-12:50	Luncheon Seminar 5
	Ovarian tissue cryopreservation -Bench to Bedside
	Chairs: Hiroaki Kajiyama, Japan; Yukiko Katagiri, Japan
	Industry-supported Seminar by IVF JAPAN Group 9 IVF JAPAN
11:50-12:10	Technological development for fertility preservation
40.40.40.00	Shu Hashimoto, Japan
12:10-12:30	Ovarian tissue cryopreservation: Bench-to-Bedside
	- From an oncological perspective: Practice in pediatric patients -
	Kai Yamasaki, Japan

	SUNDAY, NOVEMBER 17, 2024
Room 1	
12:30-12:50	Ovarian tissue cryopreservation from the reproductive medicine side
	Tomoko Inoue, Japan
12:50-13:00	Coffee Break
13:00-14:00	Session 22
	Oral Session 5
	Chairs: W Hamish Wallace, UK; Wen Li, China
13:00-13:10	Oncofertility decisions and psychological state of female cancer patients on
	fertility preservation
	Xiao Wang, China
13:10-13:20	Effects of ovarian transplantation site on ovarian follicle and gene expression
	Seoyoung Cho, Korea
13:20-13:30	Decision perceptions and stress response of male cancer patients on urgent
	fertility preservation
	Xiao Wang, China
13:30-13:40	Five factors to increase the pregnancy rate after ovarian tissue transplantation
	Koichi Kyono, Japan
13:40-13:50	Effects of melatonin supplementation on human sperm cryopreservation:
	A systematic review and meta-analysis
	Samuel Lionardi, Indonesia
13:50-14:00	Current status of fertility preservation for male young cancer survivors in
	dokkyo medical university saitama medical center
	Toshiyuki lwahata, Japan
14:00-14:10	Coffee Break
14:10-15:30	Session 24
	Ovarian Tissue Cryopreservation
	Chairs: Claus Yding Andersen, Denmark; Pasquale Patrizio, USA
14:10-14:30	Current status and future prospects for ovarian tissue cryopreservation
	Debra A Gook, Australia
14:30-14:50	Ovarian tissue cryopreservation by vitrification system
	Yodo Sugishita, Japan
14:50-15:10	Achievements over the years on ovarian tissue cryopreservation in your
	institute including the data regarding recent success of livebirth using ovarian
	tissue vitrification technology
	Nicole Sänger, Germany
15:10-15:30	General Discussion
15:30-16:00	Closing Ceremony
	Closing Remarks: Nao Suzuki, Japan

SUNDAY, NOVEMBER 17, 2024	
Room 2	
9:00-10:20	Session 19
	ASFP Session: Fertility Preservation in Developing Countries
	Chairs: Nalini Kaul Mahajan, India; Budi Wiweko, Indonesia
9:00- 9:20	Patient's, HCP's knowledge, and referral system in fertility preservation
	Achmad Kemal Harzif, Indonesia
9:20- 9:40	Challenge and opportunities to establish fertility preservation in developing
	countries
	Padma Rekha Jirge, India
9:40-10:00	POI and fertility preservation: Challenges and opportunities
	Jihyang Kim, Korea
10:00-10:10	Short Comment: Nalini Kaul Mahajan, India; Budi Wiweko, Indonesia
10:10-10:20	General Discussion
10:20-10:30	Break
10:30-11:30	Session 21
	Benign Disease 2: Turner syndrome
40.00.40.50	Chairs: Chii-Ruey Tzeng, Taiwan; Glenn L. Schattman, USA
10:30-10:50	Fertility preservation in young patients with Turner syndrome
10:50-11:10	Marie-Madeleine Dolmans, Belgium
10:50-11:10	A series of four ovary allotransplants requiring immunosuppression
11:10-11:30	Sherman Silber, USA General Discussion
11:30-11:50	Break
11:50-12:50	Luncheon Seminar 6
11.00 12.00	Breast Cancer
	Chair: Chikako Shimizu, Japan
11:50-12:20	The efficacy and safety of pembrolizumab + chemotherapy in patients with
	early triple negative breast cancer
	Shinji Ohno, Japan
	Industry-supported Seminar by MSD K.K.
12:20-12:50	Basic research results on the ovarian toxicity of immunotherapies
	Karla Hutt, Australia
12:50-13:00	Coffee Break
13:00-14:00	Session 23
	Oral Session 6
	Chairs: Chang Suk Suh, Korea; Jung Ryeol Lee, Korea
13:00-13:10	Analysis of fertility preservation status in young breast cancer patients
	Kejin Wu, China

	SUNDAY, NOVEMBER 17, 2024
Room 2	
13:10-13:20	Cell-based menopausal hormone therapy using injectable biomimetic artificial ovary with lower breast cancer risk Yang Heeseon , Korea
13:20-13:30	The step by step video presentation and analysis of the single-port laparoscopic partial ovariectomy for ovarian tissue cryopreservation Hexia Xia , China
13:30-13:40	Application of pump-free microfluidic system utilizing hydrostatic pressure on human cumulus cell culture: A model for long-term in vitro follicle growth Paweena Thuwanut , Thailand
13:40-13:50	The significance of genetic counseling in fertility preservation for cancer patients Ying Zhang, China
13:50-14:00	Long term safety of controlled ovarian stimulation for fertility preservation prior to chemotherapy treatment in breast cancer patients Moran Shapira , Israel
14:00-14:10	Coffee Break
14:10-15:30	Session 25 New Technology 2 Chairs: Terri L Woodard , USA; Luciana Cacciottola , Belgium
14:10-14:35	A microengineered niche for high throughput and high content analysis of organoids Emna Ouni, France
14:35-14:55	A spatiotemporal molecular atlas of the human ovarian cortex after vitrification- thawing procedure Wen Li , China
14:55-15:15	Hormone autocrination by vascularized hydrogel delivery of ovary spheroids to rescue ovarian dysfunctions Young Sik Choi, Korea
15:15-15:30	General Discussion

LIST OF POSTER PRESENTATIONS

	SATURDAY, NOVEMBER 16, 2024
Poster	
A-1	SOLID SURFACE VITRIFICATION AND CLOSED-STORAGE SYSTEM OF HUMAN OOCYTES: THE HONG KONG EXPERIENCE Kevin KW Lam, <i>Hong Kong</i>
A-2	RNA-Seq TRANSCRIPTOME PROFILE OF MOUSE OOCYTES AFTER VITRIFICATION USING LOWER CONCENTRATIONS OF CRYOPROTECTANTS Qiu Juan, <i>China</i>
A-3	ANALYSIS OF 134 BIRTHS FROM CRYOPRESERVED OOCYTES AT FOUR REPRODUCTIVE CENTERS Mikoto Fujita, <i>Japan</i>
A-4	MAINTAINING TESTOSTERONE THERAPY THROUGHOUT OVARIAN STIMULATION FOR TRANSMASCULINE INDIVIDUALS: A SYSTEMATIC REVIEW Jennia Michaeli, Canada
A-5	COMPARISON OF THE NUMBER OF OOCYTES COLLECTED AND IVM(IN VITRO MATURATION) RATES USING DIFFERENT INDUCTION METHOD FOR CANCER PATIENT Hiroaki Yoshida, <i>Japan</i>
A-6	OOCYTE CRYOPRESERVATION: A COMPREHENSIVE ANALYSIS OF LIVE BIRTH RATE BY AGE AND INDICATION OF TREATMENT Michal Kirshenbaum, <i>Australia</i>
A-7	SAFETY OF CONTROLLED OVARIAN STIMULATION FOR FERTILITY PRESERVATION IN CANCER PATIENTS Hiromu Okaki, <i>Japan</i>
A-8	NEW INSIGHTS INTO THE OPTIMAL VITRIFICATION TIME FOR OOCYTE CRYOPRESERVATION IN BALANCING THE CYTOPLASMIC MATURATION AND IN-VITRO AGEING Xiangfei Wang, <i>China</i>
A-9	RESULTS FROM TWENTY YEARS OF OVARIAN TISSUE TRANSPLANTATION IN FRANCE DATA FROM THE GRECOT REGISTER (RESEARCH AND STUDY GROUP FOR OVARIAN AND TESTICULAR CRYOPRESERVATION) Christophe Roux, France
A-10	THE RESEARCH OF HUMAN OVARIAN TISSUE CRYOINJURY BASED ON SINGLE-CELL TRANSCRIPTOMIC ANALYSIS Di Sun, China
A-11	ENHANCING OVARIAN RESERVE ASSESSMENT IN WOMEN WITH ENDOMETRIOSIS: A COMPARISON OF MRI-BASED IMAGING MARKERS WITH ANTI-MULLERIAN HORMONE Jong Kil Joo, Korea
A-12	COMPARATIVE EFFECTIVENESS OFVITRIFICATION AND SLOW FREEZING AFTER HETEROTOPIC TRANSPLANTATION OF HUMAN OVARIAN TISSUE Yucui Zeng, <i>China</i>
A-13	VITRIFICATION OF HUMAN OVARIAN TISSUE: CAN IT REPLACE THE SLOW FREEZING METHOD? A COMPARISON OF ANGIOGENIC POTENTIAL AND APOPTOTIC CHANGES Andreas Schallmoser, <i>Germany</i>

LIST OF POSTER PRESENTATIONS

SATURDAY, NOVEMBER 16, 2024	
Poster	
A-14	A CASE IN WHICH MATURE OOCYTE COULD BE RETRIEVED DURING LAPAROSCOPIC SURGERY FOR OVARIAN TISSUE CRYOPRESERVATION FOLLOWING HCG INJECTION Hiroyuki Okimura, <i>Japan</i>
A-15	RAPAMYCIN INHIBITS THE Akt/mTOR PATHWAY TO ENHANCE FOLLICLE SURVIVAL AND FERTILITY RESTORATION IN OVARIAN TISSUE TRANSPLANTATION Jules Bindels, <i>Belgium</i>
A-16	FERTILITY PRESERVATION IN FEMALE CANCER PATIENTS: CASE SERIES AND METHODOLOGICAL CHALLENGES Abraham Tombe, <i>Indonesia</i>
A-17	ADVANCEMENTS IN OVARIAN TISSUE CRYOPRESERVATION: THE ROLE OF ENCAPSULATION IN ENHANCING CRYOPROTECTANT EFFICACY AND TISSUE VIABILITY Elnaz Zand, China
A-18	CASE REPORT LIVE BIRTH AFTER AUTOLOGOUS OVARIAN TISSUE TRANSPLANTATION IN AN ONCOLOGY PATIENT Agni Pantos, <i>Greece</i>
A-19	ASSESSMENT OF CANCER RECURRENCE RISK FOLLOWING XENOTRANSPLANTATING OF OVARIAN TISSUES WITH VARYING OVCAR3 CELL CONCENTRATIONS Yanli Liu, <i>China</i>
A-20	SINGLE CENTER EXPERIENCE OF SPERM CRYOPRESERVATION FOR CHRONIC MYELOID LEUKEMIA: ARE TYROSINE KINASE INHIBITORS TOXIC TO MALE FERTILITY? Shinnosuke Kuroda, <i>Japan</i>
A-21	EFFECT OF FREEZING AND THAWING ON EJACULATED SPERM AND SUBSEQUENT PREGNANCY AND NEONATAL OUTCOMES IN IVF Xueyi Jiang, <i>China</i>
A-23	PATIENT EXPERIENCE AND BARRIERS TO OVARIAN TISSUE CRYOPRESERVATION IN THE PEDIATRIC POPULATION IN WESTERN CANADA Alexander Tam, Canada
A-24	OVARIAN FOLLICLE DENSITY IN THE CHILD ADOLESCENT AND YOUNG ADULT CANCER POPULATION Madhura Jayasingam, Australia
A-25	PERSPECTIVES, KNOWLEDGE, AND ATTITUDE AMONG HEALTHCARE PROFESSIONALS ON FERTILITY PRESERVATION USING EGG FREEZING PROCEDURE Nur Eulis Pujiastuti Nahdiyat, <i>Indonesia</i>
A-26	THE POST OPERATIVE CARE IN TREATMENT OF CONGENITAL CERVICOVAGINAL AGENESIS AND ITS SURGICAL DESCRIPTION - A CASE SERIES Poh Ching Lee, <i>China</i>
A-27	MONITORING KEY PERFORMANCE INDICATORS IN ONCOFERTILITY CARE AT THE ROYAL CHILDREN'S HOSPITAL, MELBOURNE: AN AUSTRALIAN RETROSPECTIVE COHORT STUDY Emily K Andrew, Australia

LIST OF POSTER PRESENTATIONS

	SATURDAY, NOVEMBER 16, 2024
Poster	
A-28	THE IMPACT OF VALGANCICLOVIR ADMINISTRATION ON FERTILITY IN CASES OF CONGENITAL CYTOMEGALOVIRUS INFECTION Seiko Higa, Japan
A-29	KNOWLEDGE, PRACTICES, ATTITUDES AND BARRIERS TO FERTILITY PRESERVATION COUNSELING AND SERVICES FOR CHILDREN AND ADOLESCENTS: PERSPECTIVES AMONGST HEALTHCARE PROVIDERS IN A PIONEERING ONCOFERTILITY CENTRE IN MALAYSIA Anizah Ali, <i>Malaysia</i>
A-30	NIACIN IMPROVES GLUTATHIONE SYNTHESIS OF PORCINE IN VITRO GROWN OOCYTE Takayuki Yamochi, Japan
A-31	THE PLACE OF IVM IN OOCYTE CRYOPRESERVATION Anh H Le, Viet Nam
A-32	EFFECT ANALYSIS OF IN VITRO MATURATION FOR IMMATURE OOCYTES IN THE INTRACYTOPLASMIC SPERM INJECTION CYCLE Shanshan Du, <i>China</i>
A-33	RAPAMYCIN PROMOTES GVBD BY ENHANCING CYCLIN B1 ACCUMULATION IN HUMAN AND MOUSE IMMATURE OOCYTE Lixia Zhu, <i>China</i>
A-34	MINIMIZING TESTICULAR SPERM RETRIEVAL-RELATED INJURY AND ENHANCING EMBRYO QUALITY AND PREGNANCY OUTCOMES WITH UNEXPECTEDLY FROZEN EJACULATED SEMEN IN OBSTRUCTIVE AZOOSPERMIA: A CLINICAL CASE STUDY Li Wang, China
A-35	THE OVARIAN RESERVE ASSESSMENT USING ANTI-MULLERIAN HORMONE (AMH) IN WOMEN WITH NEWLY DIAGNOSED LYMPHOMA Mohd Faizal F Ahmad, <i>Malaysia</i>
A-36	A CASE OF SPONTANEOUS PREGNANCY AND DELIVERY AFTER CHEMOTHERAPY WITH GnRH AGONIST FOR MALIGNANT LYMPHOMA Emi Harada, Japan
A-37	ENVIRONMENTAL NOVEL PER-AND POLYFLUOROALKYL SUBSTANCES IN FEMALE SERUM AND ASSOCIATION WITH PREMATURE OVARIAN INSUFFICIENCY: A CASE–CONTROL STUDY Rui Qiao, China
A-38	A MULTICENTER PROSPECTIVE COHORT STUDY TO ESTABLISH A PREDICTIVE MODEL FOR OVARIAN RESERVE CAPACITY OF AYA FEMALE CANCER PATIENTS AFTER CANCER TREATMENT IN JAPAN; INTRODUCTION OF STUDY PROTOCOL Satoshi Kubota, Japan
A-39	THE MAJOR FACILITATOR FAMILY MEMBER SVOP UPREGULATED IN CHEMOTHERAPY- INDUCED ACUTE OVARIAN DAMAGE Li Zhang, <i>China</i>
A-40	OPTION FOR CONSERVATIVE SURGERY TYPE FOR MALIGNANT OVARIAN TUMOR: CASE SERIES REPORT Syamel Muhammad, Indonesia

	SATURDAY, NOVEMBER 16, 2024	
Poster		
A-41	THERAPEUTIC POTENTIAL OF CURCUMIN-LOADED NANOPARTICLES IN PRESERVING OVARIAN RESERVE IN CYCLOPHOSPHAMIDE-INDUCED MOUSE BURNOUT MODELS Jungyoung Yoo, Korea	
A-42	THE MECHANISMS OF ASPIRIN AGAINST THE GONADOTOXICITY OF CHEMOTHERAPEUTIC AGENTS VALIDATED USING IN VITRO CULTURE OF HUMAN OVARIAN TISSUE Chu-Chun Huang, <i>Taiwan</i>	
A-43	LONG-TERM SURVIVAL OF CANCER PATIENTS UNDERGOING FERTILITY PRESERVATION VIA CONTROLLED OVARIAN STIMULATION BEFORE CHEMOTHERAPY Orestis Tsonis, UK	
A-44	A RETROSPECTIVE ANALYSIS OF BREAST CANCER PATIENTS WHO VISITED THE ONCOFERTILITY CLINIC AT OUR HOSPITAL Taro Kuwayama, <i>Japan</i>	
A-45	RAPID OVARIAN RESERVE DEPLETION AFTER CHEMOTHERAPY IN YOUNG WOMEN WITH BREAST CANCER: IS OVARIAN TISSUE CRYOPRESERVATION STILL A SUITABLE OPTION? Sarrah Ayuandari, Indonesia	
A-46	THE FERTILITY CONCERNS IN YOUNG BREAST CANCER PATIENTS (FELICE) TRIAL Tomomi Abe, Japan	
A-47	KNOWLEDGE, ATTITUDES, AND BEHAVIOURS OF DOCTORS AND FEMALE PATIENTS WITH BREAST CANCER TOWARDS OVARIAN PRESERVATION AND ITS SUPPORTING FACTORS Kieran Pasha Ivan Sini, Indonesia	
A-48	SUCCESSFUL AUTOLOGOUS FROZEN-THAWED OVARIAN TISSUE TRANSPLANTATION IN AN ACUTE MYELOID LEUKEMIA SURVIVOR FOLLOWING EXTENSIVE MRD SCREENING Michelle Soares, <i>Belgium</i>	
A-49	FACTORS AFFECTING THE LONG-TERM PROGNOSIS OF PATIENTS IN THE AYA GENERATION WITH EPITHELIAL OVARIAN CANCER: A MULTICENTER PROPENSITY SCORE MATCHING ANALYSIS Emiri Miyamoto, Japan	
A-50	EFFECTIVITY OF FERTILITY-SPARING STRATEGIES IN IMPROVING PREGNANCY RATES FOR ADOLESCENTS AND YOUNG ADULTS WITH CERVICAL CANCER: A SYSTEMATIC REVIEW Nabila A Arsyad Temenggung, <i>Indonesia</i>	
A-51	DELAYED CONSERVATIVE SURGERY IN SUSPECTED MALIGNANT OVARIAN MASS DURING PREGNANCY IN YOUNG WOMEN Nur Eulis Pujiastuti Nahdiyat, Indonesia	
A-52	COMPARISON OF ASSISTED REPRODUCTIVE TECHNOLOGY LABORATORY OUTCOMES BETWEEN PATIENTS WITH MALIGNANT TUMORS AND PATIENTS WITH TUBAL FACTOR INFERTILITY	
	Ran Shen, <i>China</i>	

	SATURDAY, NOVEMBER 16, 2024
Poster	
A-53	SUCCESSFUL TREATMENT IN A PATIENT WITH AZOOSPERMIA DUE TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT Kota Shimokihara, Japan
A-54	OUTCOMES OF FERTILITY PRESERVATION IN CANCER PATIENTS: A NETWORK META- ANALYSIS COMPARING EMBRYO, OOCYTE, AND OVARIAN TISSUE CRYOPRESERVATION TECHNIQUES Shakira Amirah, Indonesia
A-55	A CASE OF A CHILD WITH A LIVE BIRTH THROUGH ASSISTED REPRODUCTIVE TECHNOLOGY AFTER LONG-TERM MANAGEMENT FOLLOWING SURGERY FOR CRANIOPHARYNGIOMA Yasushi Kawano, <i>Japan</i>
A-56	THE PROFILE OF KNOWLEDGE, ATTITUDES, AND PRACTICES OF OBSTETRICIANS AND GYNECOLOGISTS IN INDONESIA REGARDING FERTILITY PRESERVATION IN WOMEN WITH ENDOMETRIOSIS Razzan Satria, Indonesia
A-57	OVARIAN TISSUE OOCYTE-IN VITRO MATURATION FOR WOMEN FERTILITY PRESERVATION: A CASE SERIES REPORT IN VIETNAM Quang Le, Viet Nam
A-58	MELATONIN ACTS AS A FERTOPROTECTIVE AGENT FOR OOCYTES: PREVENTION OF OVARIAN RESERVE REDUCTION IN ENDOMETRIOSIS Vita Silvana, Japan
A-59	CLINICAL PRACTICE FOR FERTILITY PRESERVATION IN 67 CHILDBEARING-AGED WOMEN WITH SEVERE OR RECURRENCE ENDOMETRIOSIS Wei Huang, China
A-60	KNOWLEDGE, ATTITUDE, AND BEHAVIOUR TOWARDS FERTILITY PRESERVATION IN WOMEN WITH ENDOMETRIOSIS: A PILOT STUDY Antonia C. C. Paramitha, Indonesia
A-61	A NOVEL FERTILITY-PRESERVATIVE SURGERY WITH PROTECTION OF UTERINE STRUCTURES FOR HEALING FOR BOTH INTERNAL AND EXTERNAL TYPES OF DIFFUSE ADENOMYOSIS Ruifang Wu, <i>China</i>
A-62	THE IMPACT OF SUBFERTILITY DURATION ON WOMEN'S QUALITY OF LIFE: AN ANALYSIS OF MENSTRUAL PATTERNS, STRESS, AND SEXUAL DYSFUNCTION Anton Tanjung, Indonesia
A-63	INVESTIGATE THE MECHANISM OF RAB7 RESTORES MITOPHAGY IN AGED OOCYTES BY REGULATING MIRO1 UBIQUITINATION Xin Jin, <i>China</i>
A-64	THE IMPACT OF MALE AGE ON ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS IN POOR RESPONDER WOMEN UTILIZING FREEZE-ALL CYCLES Hyun Joo Lee, <i>Korea</i>
A-65	MFN1/2 MEDIATING OVARIAN AGING VIA PI3K/AKT PATHWAY IN GRANULOSA CELLS Limin Gao, China

	SATURDAY, NOVEMBER 16, 2024
Poster	
A-66	TRIMETHYLAMINE N-OXIDE SUPPLEMENTATION ENHANCES THE QUALITY OF OOCYTES IN POLYCYSTIC OVARY SYNDROME MICE Jiayu Huang, <i>China</i>
A-67	IS PLATELET-RICH PLASMA INTRATESTICULAR INJECTION FOR NON-OBSTRUCTIVE AZOOSPERMIA PATIENTS PROMISING? A META-ANALYSIS STUDY Lika P. Handini, Indonesia
A-68	INHIBITION OF IGFBP-4 IN GRANULOSA CELLS EXTENDS FEMALE FERTILITY AGE VIA YAP SIGNALING ACTIVATION Qianhui Hu, <i>China</i>
A-69	InOvaSGuide: A COMPREHENSIVE CALCULATION SYSTEM FOR INDIVIDUALIZED OVARIAN STIMULATION AND OHSS PREVENTION Yanhui Liu, <i>China</i>
A-70	FEASIBILITY STUDY OF A DECISION SUPPORT PROGRAM FOR PATIENTS WITH BREAST CANCER CHOOSING FERTILITY PRESERVATION THERAPY Natsuko Takahashi, <i>Japan</i>
A-71	FERTILITY PRESERVATION NETWORK IN KANAGAWA PREFECTURE (KanaOF-Net) EFFICIENTLY CONNECTED CANCER CARE PROVIDER AND FERTILITY PRESERVATION PROVIDER UNDER COVID-19 PANDEMIC Tomonari Hayama, Japan
A-72	THE INFLUENCE OF COUNSELLING IN FERTILITY PRESERVATION ON PSYCHOLOGICAL WELL-BEING AMONG FEMALE CANCER PATIENTS: A COMPREHENSIVE REVIEW THROUGH SYSTEMATIC ANALYSIS Shuffa C Mayhana, Indonesia
A-73	INTERACTION OF THE CARRIER'S GENDER AND THE INVOLVEMENT OF ACROCENTRIC CHROMOSOMES ON EMBRYONIC CHROMOSOMAL ABNORMALITIES IN PREIMPLANTATION GENETIC TESTING STRUCTURAL REARRANGEMENTS CYCLES Yanli Liu, <i>China</i>
A-74	POLYMORPHISM OF FTO GENE VARIANT RS9939609 AND FSHB GENE VARIANT RS6169 IN INDONESIAN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME Hilma P Lubis, Indonesia
A-75	ASSESSING THE IMPACT OF PSYCHOTROPIC MEDICATIONS ON FERTILITY Madhavi Singh, Australia
A-76	EFFECT OF A WEB-BASED FERTILITY PRESERVATION TRAINING PROGRAM FOR MEDICAL PROFESSIONALS IN JAPAN Masanori Ono, <i>Japan</i>
A-77	THE COMPARISON OF HIGHLY PURIFIED HUMAN MENOPAUSAL GONADOTROPHIN(HP- hMG) VERSUS LETROZOLE COMBINED WITH RECOMBINANT FOLLICLE-STIMULATING HORMONE (rFSH) IN INTRAUTERINE INSEMINATION Irene Sinta Febriana, <i>Indonesia</i>
A-78	TRENDS IN FERTILITY PRESERVATION TREATMENTS FOR CANCER PATIENTS IN JAPAN UNTIL 2023 YEAR: ANALYSIS FROM JAPAN ONCOFERTILITY REGISTRY Takao Kawai, Japan

SATURDAY, NOVEMBER 16, 2024	
Poster	
A-79	SCREENING AND BIOINFORMATICS ANALYSIS OF KEY GENES ASSOCIATED WITH FERROPTOSIS IN THE ECTOPIC ENDOMETRIUM OF ENDOMETRIOSIS Jiayu Huang, <i>China</i>
A-80	PUBLIC FERTILITY PRESERVATION PROGRAMME FOR CANCER PATIENTS IN HONG KONG Jennifer K.Y. Ko, <i>Hong Kong</i>
A-81	CONSIDERATION OF REVISING THE RISK CLASSIFICATION TABLE IN THE JSCO FERTILITY PRESERVATION GUIDELINES IN 2017 Masahito Yonemura, <i>Japan</i>
A-82	EVALUATING OVARIAN RESERVE MARKERS IN IVF PATIENTS FACING AMH AND AFC DISCORDANCE Eun Hee Yu, <i>Korea</i>
A-83	EFFICACY OF PLATELET-RICH PLASMA THERAPY IN WOMEN WITH DIMINISHED OVARIAN RESERVE: A PRELIMINARY STUDY Thi-My-Trang Luong, <i>Taiwan</i>
A-84	THE NEW REGIMEN OF OVARIAN STIMULATION WITH SIMPLIFIED DOSAGE EQUIVALENT FOLLITROPIN DELTA COMPARED WITH FOLLITROPIN ALFA FOR INTRAUTERINE INSEMINATION IN INDONESIAN WOMEN Hilma P Lubis, Indonesia
A-85	DEVELOPMENT OF ARTIFICIAL OVARIES USING DECELLULARIZED MOUSE OVARIAN TISSUE Yu Wakimoto, Japan
A-86	HEALTHCARE PROFESSIONAL VIEWS ON FERTILITY PRESERVATION IN REPRODUCTIVE AGED WOMEN WITH CANCER: A SYSTEMATIC REVIEW Febriyan Nanda Satria, Indonesia
A-87	CAUSAL EXAMINATION OF THE SMOKING-ENDOMETRIOSIS ASSOCIATION USING MENDELIAN RANDOMIZATION: INSIGHTS FROM LARGE-SCALE GENOME-WIDE DATA Ruolin Mao, China
A-88	THE SAFETY OF INFERTILE PATIENTS WITH RECURRENT BORDERLINE OVARIAN TUMOR UNDERGO CONTROLLED OVARIAN HYPERSTIMULATION/IN VITRO FERTILIZATION BEFORE SURGERY Xinyu Zhang, China
A-89	UTILIZATION OF SEMEN SAMPLE BY CANCER PATIENTS FOR FERTILITY TREATMENT Chiou Fen Carine To, Singapore
A-90	FERTILITY-SPARING HORMONAL THERAPY FOR ENDOMETRIAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FERTILITY PRESERVATION, COMPLETE RESPONSE, AND REMISSION OUTCOMES Valerie Josephine Dirjayanto, Indonesia
A-93	THE CRUCIAL ROLE OF HFM1 IN REGULATING FUS UBIQUITINATION AND LOCALIZATION FOR OOCYTE MEIOSIS PROPHASE I PROGRESSION IN MICE Danhua Pu, China

	SATURDAY, NOVEMBER 16, 2024	
Poster		
A-103	hAMSCs-DERIVED EXOSOMES IMPROVE MATURATION AND DEVELOPMENTAL	
	POTENTIAL OF OOCYTES CULTURED IN VITRO AFTER CYCLOPHOSPHAMIDE	
	Xiang Ma, <i>China</i>	
A-104	CHALLENGE TOWARDS UTILIZATION OF FIRST POLAR BODY GENOME IN FERTILITY-	
	SPARING TREATMENT CONDITION	
	Masahito Tachibana, <i>Japan</i>	

	SUNDAY, NOVEMBER 17, 2024
Poster	
B-1	THE PRELIMINARY STUDY ON THE IMPROVEMENT OF OOCYTE VITRIFICATION AND THAWING Hongxing Li, <i>China</i>
B-2	TREND IN MEDICALLY INDICATED OOCYTE AND EMBRYO FREEZING AND A CASE OF PREGNANCY FOR CANCER PATIENT USING FROZEN-THAWED OOCYTES UNDER COVID-19 PANDEMIC AT OUR CLINIC Miyako Funabiki, <i>Japan</i>
B-3	OBSTETRIC OUTCOMES FOLLOWING VITRIFICATION OF MOUSE OOCYTES WITH LOWER CONCENTRATIONS OF CRYOPROTECTANTS Qiu Juan, <i>China</i>
B-4	A CASE OF OOCYTE FREEZING IN A GIRL WITH LEUKEMIA WHO HAD NOT YET STARTED MENSTRUATING Manami Miyashita, <i>Japan</i>
B-5	LYCOPENE IMPROVES EMBRYO DEVELOPMENT OF VITRIFIED OOCYTES BY REBALANCING INTRACELLULAR REDOX ENVIRONMENT Songmao Li, <i>China</i>
B-6	COMPARATIVE RETROSPECTIVE ANALYSIS OF OOCYTE CRYOPRESERVATION CYCLES IN FEMALE ADOLESCENTS AND YOUNG ADULTS AT RISK FOR INFERTILITY Terri L Woodard, USA
B-7	CURRENT STATUS OF DECISION SUPPORT AND FERTILITY PRESERVATION AT OUTPATIENT CONSULTATION SERVICE CONCERNING FERTILITY PRESERVATION IN NAGOYA UNIVERSITY HOSPITAL Shohei Iyoshi, Japan
B-8	MITIGATING CPA TOXICITY AND PRESERVING MITOCHONDRIAL FUNCTION IN OOCYTE CRYOPRESERVATION USING ULTRA-FAST AND FAST VITRIFICATION METHODS JungRan Cho, Korea
B-9	CLINICAL ANALYSIS OF 29 PATIENTS WITH OVARIAN TISSUE CRYOPRESERVATION Wenjuan Xu, China
B-10	OVARIAN FUNCTION AND RESPONSE TO GONADOTROPINS AFTER PROLONGED EX VIVO PERFUSION OF WHOLE EWE OVARIES: A FRAMEWORK FOR EFFICIENT OOCYTE RETRIEVAL AND GENE EXPRESSION ANALYSIS APPLICABLE IN FERTILITY PRESERVATION Randa Akouri, <i>Sweden</i>
B-11	OVARIAN TISSUE CRYOPRESERVATION BY VITRIFICATION METHOD: THE INITIAL EXPERIENCE IN VIETNAM Lan Thi Thu Nguyen, <i>Viet Nam</i>
B-12	RESULTS OF OVARIAN TISSUE TRANSPLANTATION (OTT) IN PATIENTS WHOSE TISSUE WAS FROZEN BEFORE THE AGE OF 14 AND FROM 14 TO 17 YEARS DATA FROM THE GRECOT (RESEARCH AND STUDY GROUP FOR OVARIAN AND TESTICULAR CRYOPRESERVATION) REGISTER Christophe Roux, <i>France</i>

	SUNDAY, NOVEMBER 17, 2024
Poster	
B-13	AP-1 ACTIVATION INDUCES GRANULOSA CELL APOPTOSIS DURING OVARY CRYOPRESERVATION Yanquan Li, <i>China</i>
B-14	EXPLORING OF THE OPTIMAL FREEZING METHOD FOR HUMAN OVARIAN TISSUE, INCLUDING DEVELOPMENT OF A NOVEL CRYOPROTECTANT Mitsuhiro Nakamura, <i>Japan</i>
B-15	URINARY BLADDER MATRIX (UBM) IMPROVES OVARIAN TRANSPLANTATION EFFICIENCY VIA PROMOTING ANGIOGENESIS Ding Haixia, <i>China</i>
B-16	CAN WE USE THE BOVINE OVARIAN MODEL TO EVALUATE A HUMAN OVARIAN TISSUE CRYOPRESERVATION QUALITY CONTROL PROGRAM? Oscar Perez, USA
B-17	OPTIMIZATION OF OVARIAN CRYOPRESERVATION TECHNOLOGY IN VITRO IN ONCOFERTILITY AND MECHANISMS Jinhua Li, <i>China</i>
B-18	TWO CASES OF ANTI-NMDA RECEPTOR ENCEPHALITIS TREATED WITH OVARIAN CRYOPRESERVATION BEFORE CPA ADMINISTRATION AT OUR HOSPITAL Tatsuya Miyake, Japan
B-19	UNDERSTANDING FERTILITY PRESERVATION CHOICES AND PATTERNS IN POST PUBERTAL FEMALES Julia Kopeika, UK
B-21	RECOVERY OF SPERMATOGENESIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE STUDY Teppei Takeshima. Japan
B-22	LIVE BIRTH AFTER LAPAROSCOPIC DRUG-FREE IN SITU OVARIAN TISSUE ACTIVATION IN A PATIENT WITH POI: A CASE REPORT Jiayi Gu, China
B-23	FIRST REPORT OF OVARIAN TISSUE CRYOPRESERVATION FOR A 6-YEAR-OLD GIRL WITH NON-MOSAIC TURNER SYNDROME (45, X) IN JAPAN: A CASE REPORT Xin Tong, Japan
B-24	Withdrawn
B-25	FILIPINO PEDIATRIC ONCOLOGISTS' KNOWLEDGE, ATTITUDES AND PRACTICES ON FERTILITY PRESERVATION Jean Erika V. Base, <i>Philippines</i>
B-26	SUPPORT OF AND ISSUES FACED BY MEDICAL CARE PROVIDERS WHO PROVIDE FERTILITY-RELATED INFORMATION TO CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH CANCER Yuko Osugi, Japan
B-27	CHARACTERISATION OF NUCLEAR AND OOCYTE ABERRATIONS IN FOLLICLES FROM OVARIAN BIOPSIES OF CHILDREN, ADOLESCENTS AND YOUNG ADULTS Madhura Jayasingam, <i>Australia</i>

	SUNDAY, NOVEMBER 17, 2024
Poster	
B-28	TIMING OF FERTILITY PRESERVATION IN TURNER SYNDROME, AN INSTITUTIONAL EXPERIENCE Poh Ching Lee, <i>Malaysia</i>
B-29	SDF-1 IMPROVES THE QUALITY AND DEVELOPMENTAL COMPETENCE OF MICE OOCYTES BY DECREASING OXIDATIVE STRESS DURING IN VITRO MATURATION Rui Long, <i>China</i>
B-30	INVESTIGATING THE IMPACT OF DIFFERENT CULTURE ENVIRONMENTS ON PHYSICAL DEVELOPMENT OF CHILDREN BORN AS A RESULT OF IN VITRO MATURATION Yuta Kasahara, Japan
B-31	ANTI-NEOPLASTIC THERAPIES DECREASE IN VITRO MATURATION (IVM) SUCCESS RATES IN HUMAN IMMATURE OOCYTES Lingbo Meng, Japan
B-32	A CASE REPORT ON FERTILITY PRESERVATION STRATEGIES: ADDRESSING CHALLENGES OF CRYPTOZOOSPERMIA AND LOW OVARIAN RESERVE IN ICSI CYCLES Li Wang, China
B-33	UPDATE ON ROSI IN INDONESIA: OUR EXPERIENCE IN BOCAH FERTILITY CLINIC Gito R. Wasian, Indonesia
B-34	AGE AND SERUM ANTI-MULLERIAN HORMONE (AMH) LEVELS AS PREDICTORS OF TIME TO RETURN OF MENSES AFTER CHEMOTHERAPY Madhavi Singh, <i>Australia</i>
B-35	LAPAROSCOPIC OVARIAN TRANSPOSITION: SURGICAL OPTION FOR FERTILITY PRESERVATION Sabhyata Gupta, India
B-36	RETROSPECTIVE OBSERVATIONAL STUDY ON THE TIMING OF MENSTRUAL RESUMPTION FOLLOWING CESSATION OF GnRH DEPOT FORMULATIONS IN PREMENOPAUSAL BREAST CANCER PATIENTS Soichiro Kashiwabara, Japan
B-37	IMPACT OF SINGLE AND MULTIPLE CHEMOTHERAPY DOSES ADMINISTERED DURING PERIPUBERTAL PERIOD ON OVARIAN FUNCTION AND LONG-TERM FERTILITY (IN MICE) Laetitia Bernet, <i>Belgium</i>
B-38	GONADOTROPIN-RELEASING HORMONE AGONISTS DURING CHEMOTHERAPY FOR FERTILITY PRESERVATION IN REPRODUCTIVE AGE WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS Aldaffa Ghiffary Halim, Indonesia
B-39	RAPAMYCIN REPAIRS CHEMO-INDUCED PREMATURE OVARIAN FAILURE BY PROMOTING OVARIAN GRANULAR CELL EXOSOME SECRETION THROUGH IFN-Ι/ ISG15 SIGNAL PATHWAY Yan Ma, China
B-40	A CASE REPORT OF RHABDOMYOSARCOMA REQUIRING OVARIAN RELEASE FOR OVULATION PAIN FOLLOWING LAPAROSCOPIC OVARIAN TRANSPOSITION Yuko Shimoji, <i>Japan</i>

	SUNDAY, NOVEMBER 17, 2024
Poster	
B-41	STUDY ON THE MECHANISM OF HUMAN UMBILICAL CORD MESENCHYMAL STEM CELL-DERIVED EXOSOMES INHIBITING FERROPTOSIS IN OVARIAN GRANULOSA CELLS TO AMELIORATE CHEMOTHERAPY-INDUCED OVARIAN DAMAGE Jinhua Li, <i>China</i>
B-43	SUCCESSFUL LIVE BIRTH OF A CRYOPRESERVED EMBRYO AFTER THE IVM FERTILITY PRESERVATION PROGRAM IN A PATIENT WITH A BORDERLINE OVARIAN TUMOR AFTER LAPAROSCOPIC OOPHORECTOMY ON THE LEFT AND CYSTECTOMY ON THE RIGHT Ildar Iskhakov, <i>Cambodia</i>
B-44	DEVELOPMENT OF A PREDICTIVE MODEL FOR OVARIAN DOSE FOR FERTILITY PRESERVATION IN PEDIATRIC WHOLE-CRANIOSPINAL IRRADIATION Eiichi Maehara, Japan
B-45	IS BEARING MY OWN CHILD A DREAM IMPOSSIBLE TO FULFILL? PREGNANCY IN METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER Keh Yee Tan, <i>Malaysia</i>
B-46	PROGNOSIS, FERTILITY PRESERVATION TRENDS, AND PREGNANCY OUTCOMES IN YOUNG PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER Akemi Kataoka, Japan
B-47	CHEMOTHERAPY-INDUCED AMENORRHEA IN PREMENOPAUSAL BREAST CANCER PATIENTS TREATED WITH DOCETAXEL AND CYCLOPHOSPHAMIDE Saori Kawai, <i>Japan</i>
B-48	CASE REPORT OF AN ADOLESCENT-YOUNG ADULT PATIENT WITH HEREDITARY BREAST AND OVARIAN CANCER WHO HAD TWO CHILDREN AFTER BREAST CANCER TREATMENT Taeko Hyuga, <i>Japan</i>
B-49	OOCYTE CRYOPRESERVATION OUTCOMES IN WOMEN WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING CHEMOTHERAPY: A SYSTEMATIC REVIEW AND META- ANALYSIS Stephanie Dufour, Canada
B-50	FERTILITY-PRESERVING TREATMENT OF CERVICAL CANCER AND ENDOMETRIAL CANCER Nhan T. Vo, <i>Viet Nam</i>
B-51	A CASE OF NATURAL PREGNANCY AND DELIVERY AFTER CONDUCTING OPEN RADICAL TRACHELECTOMY FOR STAGE 1B1 CERVICAL CANCER WITH AN EXTROVERTED 35 MM TUMOR IN DIAMETER Tateki Tsutsui, <i>Japan</i>
B-52	SMOOTH MUSCLE TUMOUR OF UNCERTAIN MALIGNANT POTENTIAL (STUMP) AND FERTILITY PRESERVATION : A RARE CASE REPORT Mondale Saputra, Indonesia
B-53	CURRENT REPRODUCTIVE MEDICINE PRACTICES FOR CAYA CANCER PATIENTS AT OUR REPRODUCTIVE CENTER Akihiro Ikenaga, <i>Japan</i>

SUNDAY, NOVEMBER 17, 2024	
Poster	
B-54	SUCCESSFUL LIVE BIRTH OF TRANSFERRED CRYOPRESERVED EMBRYO AFTER HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR PSEUDOMYXOMA PERITONEI Yoshiko Saito, Japan
B-55	PRESERVATION OF OVARIAN BIOLOGICAL AGE IN ENDOMETRIOSIS PATIENTS UNDERWENT LONG-TERM MEDICAL TREATMENT IN CIPTO MANGUNKUSUMO HOSPITAL JAKARTA Aprilia Asthasari Siregar, Indonesia
B-56	REPRODUCTIVE OUTCOMES AFTER MYOMECTOMY: INTRACAPSULAR ROTARY-CUT PROCEDURE (IRCP) VERSUS CONVENTIONAL MYOMECTOMY(CM) Liping Zeng, <i>China</i>
B-57	ADENOMYOSIS AND/OR ENDOMETRIOSIS CYSTS PATIENTS OFFERED COMPARABLE PREGNANCY CHANCE WITH OVARIAN STIMULATION Nadia Shafira, Indonesia
B-58	A CASE OF PREGNANCY AFTER OVARIAN CRYOPRESERVATION, OVARIAN TRANSPOSITION, PREOPERATIVE RADIOTHERAPY, AND COMPLETE RESECTION FOR A SOLITARY FIBROUS TUMOR IN THE PELVIS Hideaki Yajima, Japan
B-59	COMPARING OOCYTE, EMBRYO, AND OVARIAN TISSUE FOR FERTILITY PRESERVATION IN ENDOMETRIOSIS PATIENTS: A SYSTEMATIC REVIEW AND META- ANALYSIS Shakira Amirah, Indonesia
B-60	SINGLE-CELL RNA SEQUENCING REVEALS PERIPHERAL IMMUNE CELL SENESCENCE AND INFLAMMATORY PHENOTYPES IN PATIENTS WITH PREMATURE OVARIAN FAILURE Yanhui Liu, <i>China</i>
B-61	USEFULNESS OF THE HUMAN IMMORTALIZED GRANULOSA CELL TO EVALUATE FOLLICLE DEVELOPMENT AND ITS DISTURBANCE Akira Iwase, Japan
B-62	miR-484 AS A POTENTIAL MOLECULAR BIOMARKER IN CHRONIC ENDOMETRITIS FOR PATIENTS WITH RECURRENT PREGNANCY LOSS Jen-Yu Wen, <i>Taiwan</i>
B-63	ELUCIDATING THE GENE EXPRESSION OF GREM1 IN CUMULUS CELLS AND ITS ASSOCIATION WITH HOMA-IR AMONG PCOS WOMEN Muhammad Azrai AA Abu, <i>Malaysia</i>
B-64	RE-CRYOPRESERVATION IMPAIRS BLASTOCYST IMPLANTATION POTENTIAL VIA ACTIVATED ENDOPLASMIC RETICULUM STRESS PATHWAY AND INDUCED APOPTOSIS Meng Wang, <i>China</i>
B-65	EVALUATION OF SERUM AMH USING SELF-ADMINISTERED KIT AND STANDARD VENIPUNCTURE AMONG KOREAN REPRODUCTIVE- AGED WOMEN Charise Mae C. Malabanan, <i>Korea</i>

	SUNDAY, NOVEMBER 17, 2024
Poster	
B-66	HAWKEYE SURGERY FOR PATIENTS WITH PERSISTENT AZOOSPERMIA AFTER ANTICANCER CHEMOTHERAPY Hiroshi Okada, <i>Japan</i>
B-67	RECOGNITION OF MIDWIVES INTERVENING IN FERTILITY SUPPORT IN FEMALE ONCOFERTILITY -INVESTIGATIONS INTO ONCOLOGISTS, NURSES, AND MIDWIVES- Akemi Nasu, Japan
B-68	REALITY OF FERTILITY PRESERVATION DECISIONS IN WOMEN DIAGNOSED WITH BREAST CANCER Keiko Kamitani, <i>Japan</i>
B-69	SOCIAL SUPPORT FOR FERTILITY PROTECTION IN SHANGHAI Lijun Zhu, <i>China</i>
B-70	ONCOFERTILITY-RELATED PSYCHO-EDUCATIONAL THERAPY FOR YOUNG ADULT BREAST CANCER PATIENTS AND THEIR PARTNERS: RANDOMIZED CONTROLLED TRIAL Tomoe Koizumi, Japan
B-71	A CASE OF LATE RECURRENCE OF OVARIAN CANCER IN A YOUNG ADULT FOLLOWING FERTILITY-SPARING TREATMENT AND TWO LIVE BIRTHS Saki Tsurue, Japan
B-72	A CASE OF HEREDITARY RETINOBLASTOMA THAT CHANGED THE INDICATIONS FOR PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M) IN JAPAN Yoshiharu Nakaoka, <i>Japan</i>
B-73	NOVEL VARIANTS IN <i>PADI6</i> GENES CAUSE FEMALE INFERTILITY DUE TO EARLY EMBRYO ARREST Juepu Zhou, <i>China</i>
B-74	OBSTETRICAL OUTCOME IN PREGNANT WOMEN EXPOSED TO CHEMOTHERAPY DURING CHILDHOOD, ADOLESCENCE, OR YOUNG ADULTHOOD: A SYSTEMATIC REVIEW AND META-ANALYSIS Blandine Courbiere, <i>France</i>
B-75	THE EFFECT OF OOCYTES VITRIFICATION STORAGE TIME ON CLINICAL OUTCOME OF FROZEN EGG DONATION CYCLES Ling-Bo Cai, <i>China</i>
B-76	THE EFFICACY OF PROGESTIN-PRIMED OVARIAN STIMULATION FOR FERTILITY PRESERVATION TREATMENT COMPARED WITH GnRH ANTAGONIST PROTOCOL Yuichi Matsuzawa, Japan
B-77	AGE AT MENARCHE AND RISK OF OVARIAN HYPERSTIMULATION SYNDROME IN WOMEN UNDERGOING IVF/ICSI CYCLES: A RETROSPECTIVE COHORT STUDY Tian Li, <i>China</i>
B-78	ULTRASOUND MARKERS ON 3-DIMENSIONAL ULTRASOUND WITH POWER DOPPLER FOR PREDICTING CLINICAL PREGNANCY OUTCOMES IN EMBRYO-TRANSFER CYCLES Kyong Wook Yi, Korea

SUNDAY, NOVEMBER 17, 2024	
Poster	
B-79	AN INTERVENTION STUDY ON THE USE OF LONG-TERM REVERSIBLE CONTRACEPTION (LARC) AMONG UNMARRIED ADOLESCENTS WHO HAVE HAD ABORTIONS IN SHANGHAI, CHINA Li Du, China
B-80	FERTILITY PRESERVATION STRATEGIES IN TURNER SYNDROME PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS Syahnaz Quamila, Indonesia
B-81	PERINATAL OUTCOMES OF WOMEN CONCEIVING AT AGE 43 OR OLDER BY FREEZE- THAWED EMBRYO TRANSFER, A SURVEY USING THE DATABASE OF THE JAPAN SOCIETY OF OBSTETRICS AND GYNECOLOGY: MINISTRY OF HEALTH, LABOR AND WELFARE SCIENTIFIC RESEARCH GROUP Toshiaki Yasuoka, <i>Japan</i>
B-82	CHANGES IN AMH COMPARED TO SIZE AFTER SCLEROTHERAPY IN ENDOMETRIOMA PATIENTS Hye Jin Chang, <i>Korea</i>
B-83	ESTABLISHMENT OF A FERTILITY PRESERVATION NETWORK WITH ONLINE CONSULTATION SYSTEM IN NARA Mayuko Ichikawa, Japan
B-84	DILEMMA IN PRACTICING FERTILITY PRESERVATION IN LOW RESOURCE SETTING: A CASE REPORT Fridya Wulandari, Indonesia
B-85	THREE-DIMENSIONAL VISUALISATION OF HUMAN OVARIAN FOLLICLES USING A WHOLE-MOUNT IMMUNOLABELLING AND OPTICAL TISSUE CLEARING METHOD Suzannah A Williams, <i>UK</i>
B-86	DOES LOW BIRTH WEIGHT HAVE AN EFFECT ON OVARIAN RESERVE? Chen Nahshon, Israel
B-87	CLINICAL OUTCOME ANALYSIS OF DIFFERENT CONTROLLED OVARIAN STIMULATION REGIMEN IN PATIENTS WITH OVARIAN BORDERLINE TUMOR Liang Liang, <i>China</i>
B-88	PREDICTING FERTILITY IN YOUNG BOYS AFTER GONADOTOXIC TREATMENTS–RECOVERY OF SPERMATOGENESIS Margaret Zacharin, Australia
B-89	THE EPIGENETIC CHANGES OF MOUSE OOCYTES AFTER VITRIFICATION: BASE ON SINGLE-CELL MULTI-OMICS SEQUENCING ANALYSIS Xiaoqing He, <i>China</i>
B-90	MACROPHAGES MAY PLAY AN IMPORTANT ROLE IN REGULATING MICROENVIRONMENTAL RECONSTRUCTION AFTER HUMAN FROZEN-THAWED OVARIAN TISSUE TRANSPLANTATION Liang Wang, <i>China</i>



GENERAL INFORMATION A TO Z & SPONSORS

n

Abstracts

Online Abstracts

All abstracts from the scientific program and for poster presentations have been posted online on the congress website. Abstracts will be available for online viewing for the duration of the ISFP Congress and for an extended period of at least 12 months.



Business Meetings

ISFP Board Meeting

Date: November 16 Time: 11:00-12:00 Location: Room A1 (just past the cloakroom, meeting space at the back of the room)

ASFP Board Meeting

Date: November 16 Time: 13:00-14:00 Location: Room A1 (just past the cloakroom, meeting space at the back of the room)

Certificate of Attendance

The certificate of attendance will be available for download from your "My Page" after November 15.

Cloakroom and Storage

A cloakroom and luggage deposit room will be available on the 4th floor. The venue and the organizers are not responsible for any items lost or left behind.

Opening Hours

Friday, November 15	08:00-18:30
Saturday, November 16	07:30-17:30
Sunday, November 17	07:30-16:30

Congress Secretariat for ISFP2024

c/o Congrès Inc. E-mail: isfp2024@congre.co.jp Official site: https://www.congre.co.jp/isfp2024/ X (Twitter)

Instagram





Congress Venue

JP Tower Hall & Conference JP Tower KITTE 4th & 5th floor 2-7-2 Marunouchi, Chiyoda-ku, Tokyo, Japan 100-0005 TEL:+81-3-5222-1800

Evening Coffee Break on November 15

On the first evening, relax and enjoy some coffee, wine and beer before the final session of the afternoon.

Exhibition

The Exhibition Area will be located in the 4th floor foyer.

Opening Hours

Friday, November 15	10:00-17:00
Saturday, November 16	09:00-17:00
Sunday, November 17	09:00-14:00

Liability

The Congress Secretariat and Congress Organizers cannot accept liability for personal accidents or loss or damage to private property of participants, either during or directly arising from the ISFP Congress.

Participants are expected to make their own arrangements for health and travel insurance.

Luncheon Seminars

Before the Luncheon seminars start, lunch boxes will be provided in front of each seminar room. You can pick up a lunch box where you attend the seminar. Please note that the number of lunch boxes is limited and will be available on a first-come, first-served basis.

Name Badge

You can access your name badge sheet by signing in to "My Page," which is your personal page after registration:

- Print your name badge sheet and bring it with you.
- Upon arrival at the venue, collect a badge holder from the registration desk.
- Fold your printed badge and place it in the holder.
- · Kindly wear your badge throughout the congress.

Admission to the congress will not be allowed without badge identification. Vouchers for workshops you have booked will also be printed on your name badge sheet.

Oral Presentations

For Chairs

 Please take your seat in the "next chair seat" at least 15 minutes before the beginning of your session and kindly adhere to the time allotted for the session and each presentation.

For Speakers

• Take your seat in the "next speaker seat" 15 minutes before your presentation.

Photography and Recording Policy

Participants are asked to be respectful of your colleagues by switching cell phones to silent mode before entering the session rooms. Video and audio recording are not allowed.

Poster Presentation Room

Posters will be available for viewing on-site on Saturday and Sunday of the congress. Viewing will be divided into two groups:

- Group A on Saturday, November 16
- Group B on Sunday, November 17

Poster Mounting and Dismantling Schedule

Group Mounting Time		Dismantling Time	
Group A 08:00-09:00 on Saturday		No later than 18:00 on Saturday	
Group B	08:00-09:00 on Sunday	No later than 14:40 on Sunday	

- Pins for mounting posters are provided by the Congress Secretariat.
- Poster presenters should plan to be beside their posters to answer questions during the breaks as scheduled in the program.
- The Congress Organizer is not responsible for posters that are not removed on time.

Registration and Information Desk

The Registration and Information Desk will be located at the entrance on the 4th floor. Opening Hours

Friday, November 15	08:00-17:30
Saturday, November 16	07:30-17:00
Sunday, November 17	07:30-14:30

Speakers' Preview Desk

Speakers are requested to visit the Speakers' Preview Desk in the 4th floor foyer no later than one hour prior to the session to upload and preview their presentation.

Opening Hours

Friday, November 15	08:00-17:30
Saturday, November 16	07:30-17:00
Sunday, November 17	07:30-14:00

Safety and Security

Please do not leave any bags or other personal belongings unattended at any time, whether inside or outside the session rooms.

Tokyo City Information Desk

The desk on the 4th floor provides assistance with booking city tours and offers general tourist information on sightseeing, transportation and more in Tokyo. Supported by Tokyo Convention & Visitors Bureau

WiFi

WiFi is available in all congress areas. No password is required. SSID: isfp2024 PW: isfptokyo

For Japanese Participants Only

本会で取得可能な単位について

下記の単位が本会で取得可能です。

学術集会参加単位

第8回国際妊孕性温存学会学術集会(ISFP2024)にご参加いただくことで、以下の資格更新単位を取得できます。参加証(ネームカード)と領収書は、アカウントからダウンロードしたものをご使用いただけます。

単位名	取得可能数	申請方法
日本生殖医学会 生殖医療専門医	5ポイント	 学会参加後、以下2点のPDFまたはコピーをJSRM事務局に メール添付か郵送でご送付ください。専門医ポイントが 付与されます。 ①参加証(ネームカード) ②領収書 【送付先】 一般社団法人日本生殖医学会 事務局 〒100-0014 東京都千代田区永田町2-17-17 アイオス永田町503 E-mail: info@jsrm.or.jp
日本産婦人科医 会研修参加証	-	会員:会員ポータルの会員証QRコードをご準備ください。 単位受付PCにてQRコードを読み取ります。会期終了後、 登録済の方には単位が反映されます。(シールの配布はご ざいません) 非会員:単位受付にて芳名帳にご記入いただいた後、参加 証(シール)をお渡しいたします。大会では、シールは1枚 のみ配布いたします。芳名帳のご記入をお願いいたします。
臨床遺伝専門医	3単位	単位受付にて、芳名帳にご記入いただいた後、受講証を配 布いたします。
認定遺伝カウン セラー制度	2単位	認定更新書類ご提出の際に、ISFP2024参加証明書のコピー を添付して提出することで単位が付与されます。

For Japanese Participants Only

セッション受講単位

産婦人科領域講習

開催日時	プログラム名	会場名	単位数
11月15日(金) 14:10~15:10	Session 1 Blood Cancer	Room 1	1単位
11月15日(金) 14:10~15:10	Session 5 PGT	Room 2	1単位
11月15日(金) 17:00~18:00	Session 8 Ovarian Protection	Room 1	1単位

1) 認定講習の参加受付はJSOGアプリ、JSOGカード、で行いますので、ご出席の日本産科婦人 科学会会員は各講習会場でご提示ください(e医学会カードはご使用できません)。

2) セッション開始の10分前からセッション開始10分後までに読み取り機にかざし、出席確認をお済ませください。セッションの途中入室や途中退室は単位が認められませんのでご注意ください。

泌尿器科領域講習

開催日時	プログラム名	会場名	単位数
11月15日(金) 14:10~15:10	Session 5 PGT	Room 2	1単位
11月16日(土) 9:10~10:30	Session 10 New technology 1	Room 1	1単位
11月17日(日) 10:30~11:30	Session 20 Testicular tissue cryopreservation	Room 1	1単位

ご入場の際に受講証明引換券を配布いたします。会場内で必要事項をご記入いただき、セッション終了後、会場出口でご提出ください。受講証明書をお渡しいたします。受講証明書原本 は専門医申請更新時に必要となりますので、大切に保管ください。

Sponsors for ISFP2024



Sponsors for ISFP2024



Acknowledgements to Supporters of St. Marianna University, OBGYN

医療法人 愛育会 医療法人社団 愛育会 クリニックママ 医療法人社団 愛慈会 医療法人 愛知会 愛知病院 医療法人 アイブイエフ詠田クリニック 医療法人 浅田レディースクリニック 医療法人 杏月会 医療法人財団 逸生会 医療法人 いわき産婦人科 医療法人 うふ ワキタ産婦人科 医療法人社団 神谷レディースクリニック 北村医院 医療法人 絹谷産婦人科 医療法人社団 暁慶会はらメディカルクリニック 医療法人 蔵本ウイメンズクリニック 慶應義塾大学医学部 産婦人科学教室同窓会 医療法人社団 恵寿会 赤坂見附宮崎産婦人科 医療法人社団 こうかん会 医療法人晃陽会 中村産婦人科 古賀文敏ウイメンズクリニック 医療法人 秋桜 医療法人社団 さくら 桜井産婦人科 医療法人産育会 堀病院 医療法人社団 寿幸会 田園都市線レディースクリニック 医療法人社団 寿修会 医療法人 翔仁会 仙台ARTクリニック 湘南レディースクリニック辻堂C-X 新富士病院グループ本部 杉山産婦人科 医療法人社団 正潤会 潤レディースクリニック 医療法人社団 雪仁会 近藤クリニック 医療法人 セント・ルカ セント・ルカ産婦人科 医療法人社団 千房会 新中野女性クリニック 社会医療法人 蘇西厚生会 医療法人社団 たんぽぽ会 医療法人社団 都築会 つづきレディースクリニック 医療法人社団 桐杏会メディカルパーク湘南 一般財団法人 動脈硬化研究奨励会 医療法人 ハート 広島HARTクリニック 医療法人 はぐくみ 医療法人社団 英ウィメンズクリニック 医療法人 ヒューマンリプロダクション つばきウイメンズクリニック 医療法人社団 雙葉会 アトレ大森はなおかレディースクリニック 的野ウィメンズクリニック 医療法人社団 ミオ・ファティリティ・クリニック 医療法人 矢野産婦人科 公益社団法人 有隣厚生会富士病院(共立産婦人科医院) 医療法人社団 陵仁会 えんどう桔梗マタニティクリニック 医療法人社団 レディースクリニック京野 医療法人社団 ローズレディースクリニック 医療法人社団 MEDICIこすぎレディースクリニック Noah ART Clinic武蔵小杉 五十嵐 豪 石渡 勇 栗林 靖 小宮山 瑞香 佐藤 聡二郎 田中温 名古 崇史 堀永 宏史(堀永産婦人科医院)

KITAZATO.

Kitazato is a Japanese global company, dedicated to assisted reproduction. We perform extensive research, development, manufacture, and marketing of medical devices and media to support a wide range of fertility treatments, from IUI to PGD.

One of our largest contributions has been the development of The Cryotop® Method, which popularized the revolutionary technique of vitrification of oocytes and embryos and secured its implementation at a global level. We are the only brand offering an ovarian tissue vitrification portfolio, as well.

Our dedicated support team collaborates with scientists, physicians, and embryologists worldwide to secure access to the latest knowledge and technology. We aim to provide the best quality products and services to maximize IVF clinic success, and thus contribute to the happiness and health of society, helping couples fulfil the dream of having a baby. This goal encourages us to deliver the best quality products for the entire IVF Life Cycle.

For more information www.kitazato-ivf.com

VITROLIFE GROUP

Igenomix Vitrolife

Excellence in reproductive health

Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality.

Our solutions enable optimised procedures and workflow efficiency, helping clinics to deliver outstanding results. The Vitrolife Group represents a competitive and profitable business with the best trained staff and optimal solutions for patient needs.

We take a holistic approach to reproductive health where we provide training, support and a wide range of services for clinics and laboratories worldwide. We are recognised as a leading knowledge provider in the industry as we work with both universities, research institutes, networks and communities to secure and improve successful treatment outcomes.

We are very proud to deliver cutting edge solutions to clinics enabling people around the world to fulfil their dream of having a healthy baby.

Vitrolife, K.K. & Igenomix Japan, K.K. Ryuen Building 8F, 1-3-1 Shibakoen, Minato-ku, Tokyo 105-0011 Tel: +81-3-6459-4437 Email: info.japan@vitrolife.com servicejapan@igenomix.com http://www.vitrolife.com/ja-jp http://www.igenomix.jp/



IVF JAPAN is a globally renowned institution specializing in infertility treatment, consisting of three clinics. We opened IVF Osaka Clinic in Higashi-Osaka in 1998, being among the first to implement and popularize IVM and FT. In 2003, we established IVF Namba Clinic with a focus on genetic disorders, and in 2014, we inaugurated HORAC Grand Front Osaka Clinic, which leads in innovative techniques such as mitochondrial transfer and integrative medicine. Leveraging the strengths of each clinic, to date, we have assisted over 2 million patients, consistently achieving high pregnancy rates.

We are introducing new techniques aimed at improving egg quality, advanced sperm separation methods, new culture media adjustments, and embryo observation based on time-lapse technology to better support our patients. We have established research labs "the Mitochondria Research Institute" and in Osaka Metropolitan University, and focus on developing innovative technologies led to numerous papers published in international scientific journals. Experts from around the world in this field visit our facilities for tours and come to train and learn about our cutting-edge technologies.

Address: 1-1-14 Nagata-higashi, Higashiosaka, Osaka 577-0012 TEL: +81-(0)6-4308-8824 Website: https://www.ivfosaka.com/

QIVF NAMBA CLINIC

Address: 1-17-28 Minami-horie, Nishi-ku, Osaka 550-0015 TEL: +81-(0)6-6534-8824 Website: https://www.ivfnamba.com/

HORAC GRAND FRONT OSAKA CLINIC

Address: 15F TowerB, Grand Front Osaka, 3-1 Ofuka-cho, Kita-ku, Osaka 530-0011 TEL: +81-(0)6-6377-8824 Website: https://www.ivfhorac.com/

Innovation all for the patients CHUGAI PHARMACEUTICAL CO., LTD. Roche Group

Chugai Pharmaceutical Co., Ltd., headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at https://www.chugai-pharm.co.jp/english/.

Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of €21 billion in 65 countries.

As a global leader in fertility, our primary goal is to empower individuals to realize their dream of parenthood. Our dedication to reshaping the future of fertility treatment involves close collaboration with fertility experts worldwide. Through our exceptional portfolio, unwavering ethical standards, and steadfast commitment to sustainability, we are uniquely positioned to make a meaningful impact on the lives of millions. We invite you to join us in our pursuit of reimagining excellence and enabling miracles together.



Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X(Twitter).

REPROLIFE®

REPROLIFE Inc. was established in 2010 in Japan by Dr Masashige Kuwayama, pioneer of human oocytes and embryos vitrification in Japan.

We provide CRYOTEC product line focused on cryopreservation of human oocytes and embryos, which includes vitrification and warming solutions, and equipment used in freezing and thawing.

Together with the products, REPROLIFE developed The Cryotec Method, a highly effective method with simple and flexible protocol for embryologists that leads to high survival rates of oocytes and embryos.

We constantly research and develop advanced assisted reproductive technologies and work on making our products available around the world to bring joy of having a child to as many people as possible.

株式会社(G

The last 34 years have seen CGI challenge a series of "firsts" in Japan. We were the first to bring College of American Pathologist (CAP) Accreditation services. Since that time we have seen nearly all medium and large reference laboratories become apart of the family of over 8000 globally accredited labs. We were also the first to localize CAP external proficiency testing (PT) into the Japanese language, adding hundreds of laboratories to the nearly 23,000 global CAP PT participants. We were the first to bring ISO 15189 Certification programs to Japan through TUV SUD, and later supported JAB ISO 15189 programs, and having supported some 80 laboratories gain ISO 15189 accreditation.



At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier researchintensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.



CooperSurgical®

We are a leading fertility and women's health company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life.


From reproductive care to fertility, birth, and women's health, CooperSurgical's trusted family of brands provides innovative solutions throughout your patient's lifetime.


By offering healthcare providers a comprehensive range of innovative medical solutions, we help them deliver rapid results, effective treatments, and more options at the right time.

So, women, babies, and families can experience more possibilities, faster than ever.

FLOOR PLAN

JP Tower Hall & Conference





GLOBAL PARTICIPATION

Argentina	Australia	Bangladesh	Belgium	Canada
China	Denmark	France	+ + + + Georgia	Germany
Greece	Hong Kong	India	Indonesia	Israel
Japan	Korea	Malaysia	Nigeria	Philippines
Romania	Russia	Serbia	Singapore	Sri Lanka
Sweden	Switzerland	Ť aiwan	Thailand	C* Turkey
Uganda	United Kingdom	USA	Viet Nam	






停電の不安がこれ1台で安心へ! 貴院に最適な機器選びをご提案いたします。

アイケンは200件以上の不妊治療をされる医院様へ納品実績があります。 「どれを何時間バックアップすればいいの?」「製品の違いや種類が分からない」など、 あらゆるお客様の疑問にお答えします。

「非常用バックアップ電源-安心-」のコンセントに、ご使用になる電気機器を接続するだけ。





※上記の一例、消費電力やパックアップ時間は、使用する環境や接続機器、型番により変化します。※医療機器へご使用の場合、クラス1までの機器への対応をお 願いしております。※本機はUPS (無停電電源装置) ではありません。







〒581-0013 大阪府八尾市山本町南7丁目13-27 TEL:072-943-1001

Putting Parenthood Within Reach for All Who Desire It

Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical company. For more than 50 years, Ferring has been at the forefront of innovation in reproductive medicine to support diverse family-building needs and fertility journeys to help more people become parents.

Learn more at www.ferring.com



© 2024 Ferring and the Ferring Pharmaceuticals logo are trademarks of Ferring US-RMMH-2400502







優れたビトリフィケーションを 可能にする培地



胚・卵子のストレスを低減する コンティニュアスシステム



Vit Kit-NXは、CSCM、MHMと組み合わせて 使用することで、ビトリフィケーション時の 胚と卵子へのストレスを低減します。

販売元: 富士フイルム 和光純薬株式会社

〈製品に関するお問合せ〉

東京本店 〒103-0023 東京都中央区日本橋本町二丁目4番1号 TEL:03-6225-2562 FAX:03-3242-6501 (ご注文) 戸田事業所 〒335-0026 埼玉県戸田市新曽南三丁目17番35号 TEL:048-433-2063 FAX:048-433-2112 図20120-41-1581

※本製品は薬機法の定めるところの「医薬品」「医薬部外品」ではありません。 ※FUJIFILM Irvine Scientific とそのロゴ、VIT Kit, Continuous Single Culture, およびMHMは、FUJIFILM Irvine Scientific, Inc.の商標としてさまざまな管轄区域で登録されています。 他のすべての登録機構はそれそれの所有者に風感します。




ICSI/IMSI 用電動倒立顕微鏡



顕微授精の ワークフローの 効率化を実現


Easy Operation

最小限の操作で顕微鏡を制御



工程数 75% 削減

よりクリアで明るい観察を実現



画像ご協力:藤田医科大学

60X および 100X 対物レンズは、細部の 形状まで鮮明に識別できるため、IMSI にも 対応します。



(左) CFI S プランフルオール ELWD 60XC
 (右) CFI プランアクロマート LWD IMSI 100XC



対物レンズのモジュレーターを回転させる ことで、像の陰影の方向を調節できます。 プラスチック容器も使用可能です。



(左) CFI S ブランフルオール ELWD NAMC 40XC (右) CFI アクロマート LWD NAMC 40XC

画像ご協力: The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine



株式会社 **ニコン ソリューションズ**

製品紹介サイト: www.microscope.healthcare.nikon.com/ja_JP

すべての女性に、 より豊かで、 より健やかな毎日を。

オルガノンは、女性一人ひとりの健やかな毎日の 実現に取り組むグローバルヘルスケア企業です。

さまざまなライフステージで向き合う 女性特有の症状や疾患への理解がひろがれば、 女性がより社会で活躍できる、 より良い世界が開かれていくはず。

世界の半分を占める女性の問題に フォーカスすることで、女性自身はもちろん、 その家族・仲間をも幸せにしたい。 それがきっと、社会全体の 幸せにつながっていく、と信じて。



医療関係者向け情報サイト ORGANON PRO



GNR23AD0012

オルガノン株式会社

文献請求先及び問い合わせ先 電話番号 0120-095-213 (フリーダイヤル) 受付時間 9:00~17:30 (土日祝日 当社休日を除く) 〒107-0062 東京都港区南青山1-24-3 WeWork Nogizaka www.organon.com/japan クリニック限定化粧品 ///



●乾燥肌、敏感肌でお悩みの方へ。

●ワセリン(基剤)、グリセリン(保湿剤)、水添レシチン(乳化剤)配合。

●ワセリンをナノ粒子化して乳化しやすくすると同時に、

異なるタイプの保湿剤を融合させるモイスフュージョン[™]技術採用。 ●お肌の潤いの元となる結合水をたっぷり含有。

ディーアールエックス[®] ADパーフェクトバリア フェイスミルク 容量/50mL ボディミルク 容量/130mL

販売名「ディーアールエックス AD パーフェクトバリア フェイスミルク」 販売名「ディーアールエックス AD パーフェクトバリア ボディミルク」



ゴナールエフ

ゴナールエフ

ゴナールエフ®皮下注ペンに 新しく150[®]が加わりました

[生物由来製品] 処方箋医薬品 注) 遺伝子組換えヒト卵胞刺激ホルモン(FSH)製剤

〈薬価基準収載〉



ー般名 ホリトロピン アルファ(遺伝子組換え)

注)注意---医師等の処方箋により使用すること

※ホリトロピン アルファ (遺伝子組換え)として11.12μgを含む 効能又は効果、用法及び用量、警告・禁忌を含む使用上の注意等については電子添文をご参照ください。

^{製造販売元} メルクバイオファーマ株式会社

東京都目黒区下目黒1-8-1 アルコタワー 文献請求先及び問い合わせ先:メディカル・インフォメーション フリーダイヤル 0120-870-088

> 2024年3月作成 JP-GON-00885



VITROLIFE GROUP

EXCELLENCE IN REPRODUCTIVE HEALTH

Maximise success every step of the way



Pretreatment GPDx CGT SAT Infertility Panels

IVF process eWitness Oocyte retrieval Sperm preparation Fertilisation IVF & ICSI Culture Evaluation Embryo testing **Endometrial testing** Embryo Transfer Cryopreservation

Prenatal & Postnatal

POC/NiPOC NACE

GPDx

Newborn screening









Better Health, Brighter Future

タケダは、世界中の人々の健康と、 輝かしい未来に貢献するために、 グローバルな研究開発型のバイオ医薬品企業として、 革新的な医薬品やワクチンを創出し続けます。

1781年の創業以来、受け継がれてきた価値観を大切に、 常に患者さんに寄り添い、人々と低頻関係を築き、 社会的評価を向上させ、事業を発展させることを日々の行動指針としています。



武田栗品工業株式会社 www.takeda.com/jp



2023年4月作成







Is the sushi you know the real sushi?

If you are coming to Japan, why don't you try real sushi?

In fact, the way you eat it and the taste may differ significantly from the sushi you are used to. Real Edomae sushi offers a unique experience that is quite different from what you might find elsewhere.

We invite you to not only participate in ISFP2024 but also to indulge in the authentic flavors of Edomae sushi while you're here!Z

Mt. Fuji is the most famous mountain in Japan !

Japanese people have lived with Mt. Fuji since ancient times. The highest mountain in Japan and a much-loved sacred mountain, it was registered as a UNESCO World Heritage Site in 2013, attracting many visitors from Japan and abroad.

Mt. Fuji is only about two hours by train from Tokyo, where the ISFP will be held, so you can extend your stay in Japan a little longer and go see Mt. Fuji. On the Fuji side, there are many well-known hot spring spots. Seeing Mt. Fuji up close would be a spectacular sight and very relaxing. It would be sensational to see the genuine Mt. Fuji.

Of course, Tokyo has many view spots where you can see Mt. Fuji. Please come to join the ISFP2024 TOKYO.





Do you know Ginza?

Ginza is located just a few minutes' walk from the congress venue. It's the most luxurious area in Japan, like 5th Avenue in New York.

You can buy the finest goods from all over the world, enjoy exquisite cuisine, and indulge in some window shopping.

If you are coming to Japan, why not stop by Ginza, the most prominent district in Japan?

Do you know about "Ramen" ?

Is the ramen you always see and eat really the same as the ramen in Japan? You will find out theZ difference when you come to Japan. It is very affordable, delicious, and loved all over the world. You must try it. Since you are coming to Japan, please think carefully about what you will do and enjoy before coming.





A LEW CONTRACTOR		14
	e e e e e	T I I
No. 194	A LO	
		H H
		The second

Asakusa

Do you know Asakusa? Japan is now completely westernized.

However, with its ancient Japanese history, Asakusa has the atmosphere of old Japan, such as Kyoto and Kamakura.

Why don't you try the old-fashioned meals of the common people, which you cannot eat unless you go to the area?

Senso-ji Temple is the place to go if you are coming to Tokyo.

It is a symbolic temple of Tokyo located in Asakusa. Especially, the enormous red lantern at the center of the Kaminarimon (thunder gate) is a vivid symbol of Asakusa, and is almost as famous as Sensoji Temple itself. We hope you will take the opportunity to experience a part of Japan you have never seen before.

Kawaguchiko

We often receive the request, "If I travel all the way to Japan, I want to see Mt. Fuji!"

Where is the best place to see Mt. Fuji? Have you heard of Lake Kawaguchiko? This is one of the best spots to view Mt. Fuji's spectacular scenery.

Also, Lake Kawaguchiko is known for its wonderful hot springs. Why not take a relaxing hot spring bath to relieve your daily fatigue while enjoying a breathtaking view of Mt. Fuji?

Come and discover a side of Japan you've never experienced before!



A two-and-a-half-hour train ride from Tokyo. If you head for Chiba, you will find a mountain called Nokogiriyama.

There is a viewpoint called "Jigoku-nozoki" (peeking into hell) where you can see a spectacular view. From the fantastic nature of the mountains to the sea, there are lovely views, and if you travel to Chiba, you can enjoy them.

Why not eat delicious seafood and stay overnight in Chiba?

You can see such great nature only 2 hours from Tokyo.

Tokyo Bay

Tokyo Bay is famous for its cruises.

There are all kinds of dinner cruises available, including sightseeing-only cruises, French cuisine cruises, Japanese cuisine cruises, Chinese cuisine cruises, and more.

The Tokyo Bay cruise is a great experience. If you are in Tokyo and wondering what to do, consider joining a Tokyo Bay Cruise in the evening!









Rikugien Gardens - A walk to remember the heart of waka poems entrusted to us by the samurai

Tokyo is still experiencing the lingering summer heat, but there are days that feel cool in the mornings and evenings, and we can already hear the footsteps of autumn. How are you spending your days these days?

When thinking about Tokyo, many people may imagine samurai.

Samurai were living according to the ethical code known as Bushido. Although they were educated in martial arts, they also valued cultural activities and had a strong interest in various arts.

In Tokyo, there are gardens built by samurai during the Edo period, and even today you can experience the spirit of the samurai. Rikugien is one of them.

Rikugien is a daimyo garden (Japanese feudal lord's garden) built in the Edo period (1702), and is counted as one of the two great gardens of Edo, and is currently designated as a national special scenic spot and important cultural property.

It is a stroll-style garden with artificial hill and fountain designed by Yoshiyasu Yanagisawa, a daimyo (feudal lord) who led the era along with Shogun Tsunayoshi Tokugawa, incorporating 88 waka poems and metaphors.

The garden is divided into three concepts of worlds. As you walk around and enjoy the scenery of the garden, please look for the waka poems that are incorporated in the garden.

Through the magnificent theme hidden in Rikugien, you will be able to feel the spirit of harmony that the daimyo of Edo entrusted to future generations.

Why not treat yourself to the finest Wagyu during your stay in Tokyo?

Wagyu

Speaking of Japan, have you considered indulging in Wagyu during your visit? The word "Wagyu" comes from "wa," meaning Japan, and "gyu," meaning beef. Known for its exceptional quality, rich flavor, and historical significance, Wagyu holds a special place in Japan's culinary culture. Among the most renowned varieties are Kobe, Matsusaka, and Omi beef, collectively known as the "Three Great Wagyu." These varieties have captured the hearts of food enthusiasts worldwide with their exceptional taste and quality.

Wagyu is one of the many things that astonishes visitors from abroad. In particular, Kobe beef has gained immense popularity among international celebrities, with many traveling to Japan specifically to savor this delicacy. What sets Wagyu apart from other types of beef is its distinctive aroma and tenderness. The sweet, rich fragrance of Wagyu, known as the "Wagyu beef aroma," is unparalleled. Its melt-inyour-mouth texture offers a truly unparalleled dining experience.

Whether you prefer grilled, teppanyaki, sukiyaki, or shabu-shabu, there are countless ways to enjoy Wagyu. We invite you to explore your favorite preparation and indulge in an unforgettable culinary experience.

Why not treat yourself to the finest Wagyu during your stay in Tokyo?







Kamakura

This time, we would like to introduce Kamakura.

Kamakura became the center of the country with the birth of the Kamakura Shogunate, the first samurai government in Japan, and the samurai culture was formed by the fusion of the aristocratic culture represented by Kyoto and Nara and the samurai spirit of quality and honesty. Kamakura is also famous for its many temples.

Kamakura is also a scenic area with both seaside and mountainside areas, and each area offers a completely different view.

There are also many temples with interesting sights to see, and you will never get tired of strolling around.

Kotokuin Temple, famous for the Great Buddha of Kamakura, Hokokuin Temple, famous for its bamboo garden, Jomyoji Temple, with its beautiful dry landscape garden, and Myogetsuin Temple, famous for its autumn foliage, are just a few of the many temples you will find in the area.

Why not drop by one of these temples when you come to Tokyo?

Tempura

Along with sushi, eel, and soba noodles, tempura is one of the dishes that represents Tokyo's food culture, which has been passed down since the Edo period.

Tempura is made by battering and frying ingredients such as vegetables, seafood, and meat, with an emphasis on freshness. However, it also requires great skill from craftsmen, who carefully consider which flavors to bring out from the ingredients, the thickness of the batter, and the temperature of the frying oil. The light texture when you put it in your mouth attracts people.

Tempura can be enjoyed as a reasonably priced snack, but if you're visiting Tokyo, we highly recommend experiencing traditional tempura.

Sitting at the counter and watching the live frying in front of you in an open kitchen, you'll see how Tokyo's tempura truly becomes an art form where the craftsmanship shines. The charm of tempura lies in its crispy texture and savory flavor. The thin and light fried batter enhances the flavor of the ingredients, and the deliciousness spreads in your mouth when you take a bite. Moreover, by using the most flavorful ingredients of the season, tempura maximizes the natural taste and sweetness of each ingredient.

Tempura shines with the craftsmanship that values the characteristics of the ingredients. Please try the taste of delicate craftsmen in Tokyo.







Yakitori

You'll find plenty of grilled chicken dishes around the world, but Japan offers its own special version called yakitori. While many Asian countries have their own grilled chicken dishes, Japanese yakitori has a unique flavor that you won't find anywhere else.

You absolutely must try it at least once while you're in Japan—don't miss out on this culinary delight!

We hope you enjoy your stay in Japan!

Experience Japan with Shabu-shabu

In Japan, you'll have the chance to try "shabu-shabu," a unique and high-end way to enjoy beef that you won't easily find elsewhere. Unlike steak, shabu-shabu is made by dipping thin slices of raw beef into boiling water. You can cook each slice to your preferred doneness—rare, medium, or more. Enjoy it with a special dipping sauce that enhances the flavors. This is a unique culinary experience!

Since you'll be visiting Japan, we hope you take the opportunity to fully enjoy the country and all it has to offer.

Sukiyaki – A Unique Taste of Japan

We've shared much about Japan's offerings, and today we'd like to introduce you to sukiyaki. Not many countries around the world consume raw eggs like we do here in Japan, where special handling ensures safety, making raw egg a delightful dipping sauce for sukiyaki.

This experience may sound surprising to some, but we invite you to give it a try it's worth the courage!

Discover the wonder and excitement of Japanese cuisine with sukiyaki, one of our traditional dishes. Don't miss this chance while you're here in Japan!

Tokyo Station

ISFP2024 will be held at a historic building in Marunouchi, right in front of Tokyo Station, previously known as the Japan Post Headquarters.

The venue, JP Tower Hall & Conference, is located on the 4th floor of the KITTE building, which is very conveniently located and easily accessible from Tokyo Station.

Tokyo Station itself has a long history, and you can experience the vibrant pulse of Japan's central hub right at its heart.



The 8th World Congress of the International Society for Fertility Preservation

Luncheon Seminar

13:00 - 14:00, Friday, November 15 Room1, 4th Floor, JP Tower Hall & Conference

Chair



Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Japan Dr. Nao Suzuki, M.D., Ph.D.



Speaker

Department of Obstetrics & Gynecology, **Division of Reproductive Sciences**, Yale University School of Medicine

Dr. Kutluk Oktay, M.D., Ph.D., FACOG

Lecture

Improving Ovarian Transplantation and In Vitro Primordial Follicle Growth Outcomes with Cryopreserved Tissue.

Dr. Kutluk Oktay is a leading expert in fertility preservation and ovarian biology, renowned for his groundbreaking work in ovarian transplantation and cryopreservation. His upcoming talk will cover the latest techniques with robotic surgery and neovascularization-enhancing agents to improve ovarian graft outcomes.

Additionally, he will share his latest findings on in vitro primordial follicle growth and novel approaches to extending reproductive lifespan and postponing menopause.

Official website of the congress URL: https://www.congre.co.jp/isfp2024/



Congress Secretariat c/o Congrès Inc. Onward Park Bldg., 3-10-5 Nihonbashi, Chuo-ku Tokyo

103-8276, Japan

Email: isfp2024@congre.co.jp





Co-sponsored by : ISFP2024 **Kitazato Corporation**

Ova Cryo Kit / Ova Thawing Kit

- Ovarian Tissue Vitrification -

- Media and devices for ovarian tissue vitrification and thawing.
- Square Measure is a template that helps to prepare ovary into dimensions of 10 x 10 x 1mm.
- Cryodevices are available in both closed and open system.
- Ova Rinse is medium for washing and keeping ovary to prevent it from drying before vitrification procedure. Ova Culture is recommended for extended culture after thawing.

Collaborative Development:

Prof. Nao SUZUKI, M.D., Ph.D., Obstetrics and Gynecology, St. Marianna University School of Medicine Yoshiharu MORIMOTO, M.D., Ph.D., CEO, HORAC GRAND FRONT OSAKA CLINIC







TOKYO : 1-1-8 Shibadaimon, Minato-ku, Tokyo 105-0012 JAPAN







The 8th World Congress of the International Society for Fertility Preservation

ISFP2024

Luncheon Seminar 2

13:00 - 14:00, Friday, November 15 Room 2 (Conference room B, 5F, JP Tower Hall & Conference)

Introduction to CAP Reproduction Laboratory Accreditation Program



^{Chair} Seido Takae

Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kanagawa, Japan





Speaker

Erica J. Behnke, Ph.D., HCLD (ABB) Ovation Fertility, Cincinnati, Ohio, USA

B)

College of American Pathologists, Reproductive Medicine Committee

Abstract

This presentation provides an in-depth overview of the College of American Pathologists (CAP) Reproduction Laboratory Accreditation Program (RLAP)*. As a global leader in laboratory quality assurance, CAP accredits over 8,000 laboratories worldwide, supporting high-quality, cost-effective patient care. The RLAP is specifically designed to meet the unique needs of reproductive laboratories, including those performing embryology-related procedures and semen analysis. By pursuing accreditation, laboratories demonstrate a commitment to continuous improvement, efficiency, and the highest standards of care.

Key program features include biannual peer-based inspections, customized discipline-specific checklists, and proficiency testing to ensure laboratory accuracy and compliance. The collaboration with the American Society for Reproductive Medicine and recognition by the Society for Assisted Reproductive Technologies (SART) highlights CAP' s commitment to advancing the field of reproductive medicine. Through this program, laboratories are equipped to meet regulatory standards, reduce errors, enhance performance, and ultimately improve patient care.

The presentation also covers CAP's extensive proficiency testing programs, focusing on semen analysis, embryology, and sex hormone testing, designed to support laboratories in maintaining quality and identifying areas for improvement. Additional resources, such as the Performance Analytics Dashboard, offer laboratories insights into performance trends, helping them drive continuous improvement and ensure excellence in patient testing outcomes.

*The RLAP program is designed in collaboration with the American Society for Reproductive Medicine (ASRM) and is recognised by the Society for Assisted Reproductive Technologies (SART).

Co-sponsored by :



The 8th World Congress of the ISFP Luncheon seminar 3

Cancer survivorship

Saturday, November 16 <Day 2> 12:30 – 13:50 Room 1 (4F Hall 1-2-3) Simultaneous interpretation available in Japanese

Prof. Dr. Michael von Wolff

Chair

University Womens Hospital, Bern, Switzerland

Dr. Chikako Shimizu

Fertility issues in cancer patients and survivors

National Center for Global Health and Medicine, Japan

Iatrogenic POI treatment options after cancer

Fertility preservation and infertility treatment in

- from an oncologist's perspective

University Womens Hospital, Bern, Switzerland

women with very low ovarian reserve

University Womens Hospital, Bern, Switzerland

Dr. Chikako Shimizu

Prof. Dr. Petra Stute

Prof. Dr. Michael von Wolff

National Center for Global Health and Medicine, Japan

Speakers and Presentation titles







A panel discussion will follow



Co-sponsored by: ISFP 2024 Merck





vitrolife.com | igenomix.eu VITROLIFE GROUP[™]

The 8th World Congress of the International Society for Fertility Preservation

Luncheon Seminar 4 (Day2) When It Comes to Fertility Preservation and Reproductive Genetics, What Is Best Practice for Patients?





Miyuki Harada, M.D., Ph.D. Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Japan

Speakers



Incorporating reproductive genetics into IVF: Carrier screening, PGT-M and PGT-A

Chun-I Lee, M.D., Ph.D. Lee Women's Hospital, Taiwan



Fertility preservation, oocyte vitrification and ovarian tissue cryopreservation

Debra A Gook, M.D., Ph.D. Reproductive Services, Royal Women's Hospital, Australia



When 12:30pm - 1:30pm, Saturday, 16th November 2024

Where Room 2 (Conference Room B, 5F, JP Tower Hall & Conference)



Co-sponsored by : ISFP2024 VITROLIFE GROUP





Ovarian tissue cryopreservation -Bench to Bedside

November 17, 2024 11:50am-12:50pm JP TOWER Hall & Conference 4F \[Room1 \]



Hiroaki Kajiyama Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine Yukiko Katagiri Department of Obstetrics and Gynecology, Faculty of Medicine, Toho University





Technological Development for Fertility Preservation

Shu Hashimoto Reproductive Science, Graduate School of Medicine, Osaka Metropolitan University / IVF JAPAN



From the oncology side -Practice inpediatric patients

Kai Yamasaki Department of Pediatric Hematology and Oncology, Osaka City General Hospital

From the reproductive medicine side

Tomoko Inoue HORAC Grand Front Osaka Clinic, IVF JAPAN

The 8th World Congress of the ISFP (ISFP2024) Luncheon Seminar6

Date : November 17 (Sun.), 2024 12:00~12:30

Venue JP TOWER HALL&CONFERENCE

KITTE 4th and 5th floors, 2-7-2 Marunouchi, Chiyoda-ku, Tokyo Room 2 (Conference room B, 5F, JP Tower Hall & Conference)

PROGRAM

Chairman

Chikako Shimizu

Head of Department Breast and Medical Oncology National Center for Global Health and Medicine

Lecture 12:00~12:30

The efficacy and safety of pembrolizumab + chemotherapy in patients with early triple negative breast cancer]

Speaker

Shinji Ohno

Director Social Medical Corporation Hakuaikai Sagara Hospital

Please note that we will not be able to cover your travel expenses for participating in this seminar.

Co-sponsor : The 8th World Congress of the ISFP(ISFP2024)



ISFP2024

The 8th World Congress of the International Society for Fertility Preservation



As of November 1st, 2024



Argentina LORENZO, O FABIAN



Australia Alesi, Lauren Andrew, K Emily Demyanenko, Marina Gook, Debra Hutt, Karla Jayasingam, Madhura Kirillova, Anastasia Lantsberg, Daniel McFadden, Kathryn Singh, Madhavi-Priya Stern, J Catharyn Ye, Louie Zacharin, R Margaret



Bangladesh FARUQUI, MARIAM



Belgium

BERNET, LAETITIA BINDELS, JULES CACCIOTTOLA, LUCIANA DE VOS, MICHEL DEMEESTERE, ISABELLE DOLMANS, MARIE-MADELEINE DONNEZ, JACQUES MUNAUT, CARINE SMITZ, JOHAN FERRING PHARMACEUTICALS



Canada AHN, S DIANE DUCAS, ROBIN DUFOUR, STEPHANIE ELLIOTT, JASON FOONG, C SHU GLASS, B KAREN GREENBLATT, M ELLEN JACKSON, AARON LAWRENCE, CAROLE MICHAELI, JENNIA PARKER, KIM TAM, ALEXANDER WAIS, MARTA



China CAI, LINGBO CHIAN, RI-CHENG DIAO, FEIYANG DING, HAIXIA DING, YAN DU, LI DU, SHANSHAN GAO, LIMIN GU. JIAYI GUAN, YICHUN GUO, FANGHAO HE, XIAOQING HOU, ZHEN HU, QIANHUI HUA, KEQIN HUANG, JIAYU HUANG, WEI ISKHAKOV, ILDAR

JIANG, XUEYI JIN, XIN JINGJIE, LI KUANG, YIHUI LI, CHUNYI LI, DA LI, HONGXING LI, JIAHENG LI, JINHUA LI, SONGMAO LI. TIAN LI, WEN LI, YANQUAN LIANG, LIANG LIU, JING LIU, YANHUI LIU, YANLI LONG, RUI MA, XIANG MA, YAN MAO, RUOLIN MENG, LINGBO MENG, XIANGKAI MIAO, LIU NIE, RUI QIAO, RUI QIN, MIN QIU, JUAN QU, XINFENG RAN, SHEN REN, XINLING SUN, DI SUN, NINGXIA TAN, RONGRONG TAO, HUI MIN TIAN, CONGHUI WANG, LI WANG, LIANG WANG, LING WANG, MENG WANG, MENGHAN WANG, XIANGFEI WANG, XIAO WANG, ZIRUI WEIE, ZHAO

ISFP2024 The 8th World Congress of the International Society







As of November 1st, 2024

WU, KEJIN WU, RUIFANG XIA, HEXIA XIAOYAN, LIANG XU, CONGJIAN XU, WENJUAN YAN, JIE YANG, PEIWEN YANG, SHULIN YI, YING YINGCHUN, GUO YUAN, XIAOLING YUE, JING ZAND, ELNAZ ZENG, LIPING ZENG, YUCUI ZHANG, LI ZHANG, MEILING ZHANG, WEI ZHANG, XINYU ZHANG, YING ZHAO, GANG ZHAO, JIEMI ZHOU, JUEPU ZHU, LIJUN ZHU, LIXIA



Denmark ANDERSEN, CLAUS YDING BORGBO, TANNI CADENAS, JESÚS JENSEN, B LEA JOHANNSEN, MALENE KRISTENSEN, G STINE SUBIRAN ADRADOS, CRISTINA



France

CAVALIERI, MATHILDE CHEVENIER, GRÉGORY COURBIERE, BLANDINE EUMONT, E EMMANUEL GRICOURT, SOLENNE GRYNBERG, MICHAEL GUENIFFEY, AURORE HUBERLANT, STÉPHANIE LABRUNE, ELSA OGOUMA AWORET, LUDMILLA OUNI, EMNA PECH, JEAN-CHRISTOPHE PIVER, PASCAL POIROT, CATHERINE ROUX, CHRISTOPHE SALLE, BRUNO



Georgia SHAGYROVA, ZHADYRA



Germany BENDER-LIEBENTHRON, JANA EINENKEL, REBEKKA SÄNGER, NICOLE SCHALLMOSER, ANDREAS ZIEHR, STEPHANIE



Greece PANTOS, AGNI



Hong Kong CHOY, RICHARD HIGO, SAYAKA KO, JENNIFER LAM, KEVIN KA-WAI WAN, SIU FAN REBECCA WONG, EVELYN



India DEVI, M GOURI GOSWAMI, GEETA GUPTA, SABHYATA JIRGE, PADMA REKHA KAUR, JASNEET MAHAJAN, NALINI PADGAONKAR, SHREYAS PATIL, M MADHURI PATIL, S MILIND



Indonesia AMIRAH, SHAKIRA ANGGITASWARI, A COKORDA ISTRI ARSYAD TEMENGGUNG, A NABILA AYUANDARI, SARRAH BAYUAJI, HARTANTO DEWANTO, AGUNG

SFP2024 Formula Society of the International Society of the International

The 8th World Congress of the International Society for Fertility Preservation As of November 1st, 2024

DIRJAYANTO, VALERIE JOSEPHINE FEBRIANA, IRENE SINTA HAEKAL, MOHAMMAD HALIM, ALDAFFA GHIFFARY HANDINI, P LIKA HARZIF, ACHMAD KEMAL HUTAMA, SATRIA AUDI IFFANOLIDA, A PRITTA KAMAROEKMI, S MAYA SRI LIONARDI, SAMUEL LUBIS, P HILMA MAIDARTI, MILA MAYHANA, SHUFFA CHILLA MILANO, DEO CERLOVA MORENA, H SILVIA MUHAMMAD, SYAMEL MUHARAM, R. MUTIA, KRESNA NAHDIYAT, NUR EULIS PUJIASTUTI PARAMITHA, C ANTONIA QUAMILA, SYAHNAZ SAPUTRA, MONDALE SATRIA, N FEBRIYAN SHADRINA, AMALIA SHAFIRA, NADIA SINI, FENTY WARTIANA IVAN SINI, IVAN RIZAL SINI, KIERAN PASHA IVAN SIREGAR, APRILIA ASTHASARI SUSILO, ARTHA FALENTIN PUTRI TANJUNG, ANTON TOMBE, ABRAHAM WASIAN, R GITO WIBOWO, RAZZAN SATRIA WISMAYANTI, ZEISSA RECTIFA WIWEKO, BUDI WULANDARI, FRIDYA



Israel BARAM, SHIRA DERECH-HAIM, SANAZ GIDONI, S YARIV KASHI, OREN MEIROW, DROR SHAPIRA, MORAN



Japan ABE, TOMOMI AMINO, KAZUMA AONO, FUMIHITO ASAKA, MIKU BABA, TSUYOSHI BASTANFARD, ARMIN ELHINNAWI, A MANAR FEBRI, RIRIN RAHMALA FUJITA, MIKOTO FUKUDA, AISAKU FUKUDA, YUSUKE FUNABIKI, MIYAKO FURUI, TATSURO FURUYA, NATSUMI FUTAMURA, MANABU HANDA, MIKA HARA, CHIFUMI HARADA, EMI HARADA, MIYUKI HARIZUKA, NATSUKO HASEGAWA, MAYUMI HASHIMOTO, SHU HAYAMA, TOMONARI HAYASHI, KATSUHIKO HAYASHI, NAOKO HIGA. SEIKO HIKARI, ANDO HONDA, TETSURO HORAGE, YUKI HOSODA, YUKIE HYODO, HIRONOBU HYUGA, TAEKO ICHIKAWA, MAYUKO ICHIKAWA, TOMOHIKO IKEDA, TOMOAKI

IKEMI, AYAKO IKENAGA, AKIHIRO INOUE, TOMOKO ISHIKAWA, HIROSHI ISHIZUKA, BUNPEI ITAYA, YUKIKO ITO, MASAMI IWAHATA, TOSHIYUKI IWASE, AKIRA IYOSHI, SHOHEI KAJIYAMA, HIROAKI KAKII, MARI KAKU, MIKI KAMISHIRO, SUGURU KAMITANI, KEIKO KANDA, YOSHINOBU KASAHARA, YUTA KASHIWABARA, SOICHIRO KATAGIRI, YUKIKO KATAOKA, AKEMI KATSURAGI, SHINJI KAWAI, TAKAO KAWAMURA, TOSHIHIRO **KAWANO, MAHIRU** KAWANO, YASUSHI KAWASAKI, AKIKO KELSEY, TOM KIMURA, FUMINORI KITAJIMA, MICHIO KOBAYASHI, AIRI KOIZUMI, TOMOE KONDO, EIJI KONDO, HARUHIRO KONDO, SAORI SHIGEMATSU, KOSUKE KUBOTA, SATOSHI KUDO, MASATAKA KUNITOMI, CHISATO KURAHASHI, HIROKI KURODA, SHINNOSUKE KUSAMOTO, AKARI KUWAYAMA, TARO KYONO, KOICHI MAEHARA, EIICHI MAEZAWA, TADASHI

The 8th World Congress of the International Society for Fertility Preservation





As of November 1st, 2024

MASAKI, KIYO MATSUMOTO, HIROSHI MATSUZAWA, YUICHI MEKARU, KEIKO MIYAGI, ETSUKO MIYAKE, NATSUKI MIYAKE, TATSUYA MIYAMOTO, EMIRI MIYASHITA, MANAMI MIYAZAKI, TOYOHIKO MIYOSHI, YOKO MOCHIZUKI, OSAMU MORI, YUKI MORIMOTO, YOSHIHARU MORISHIGE, KEN-ICHIROU MORITA, AKARI MURATA, TAKUYA NABETA, MOTOWO NAGAOKA, YUKIKO NAGASAKA, KAZUNORI NAGATA, YUMI NAKAMURA, KENTARO NAKAMURA, MITSUHIRO NAKAMURA, NOZOMI NAKAOKA, YOSHIHARU NASU, AKEMI NISHIOKA, MIKIKO OBATA, NAOMI OGAWA, TAKEHIKO OHNO, SHINJI OKADA, HIDETAKA OKADA, HIROSHI OKAKI, HIROMU OKAMOTO, AIKOU OKIMURA, HIROYUKI OKUNOMIYA, ASUKA ONO, MASANORI OSUGA, YUTAKA **OSUGI, YUKO** OSUKA, SATOKO OTA, KUNIAKI OTA, YOSHIKO SAITO, YOSHIKO SAJI, SHOTA SANADA, YUKO

SHIBATA, HIROKI SHIGA, NAOMI SHIMIZU, CHIKAKO SHIMOJI, YUKO SHIMOKIHARA, KOTA SHIRASAWA, HIROMITSU SILVANA, VITA SUGANO, YUKI SUGAWARA, NOBUO SUGIMOTO, KOUHEI SUGISHITA, YODO SUZUKI, NAO SUZUKI, SAORI SUZUKI, TATSUYA TACHIBANA, MASAHITO TADA, YUMA TAKADA, MAYU TAKAE, SEIDO TAKAHASHI, NATSUKO TAKAHASHI, TOSHIFUMI TAKAHASHI, YOSHIKO TAKAHASHI, YUKI TAKAI, AYA TAKAI, YASUSHI TAKAYAMA, ERINA TAKEI, KAHORI TAKESHIMA, TEPPEI TAKEUCHI, HIROKI TAKIUCHI, TSUYOSHI TANAKA, YUJI TESHIMA, AYAKA TODA, SAYAKA TOGASHI, KAZUE TOMARI, HIROYUKI TONG, XIN TSUKAMOTO, KANAKO TSURUE, SAKI TSUTSUI, TATEKI URATA, YOKO UTSUNOMIYA, TAKAFUMI VENTER, CHRIS WAKIMOTO, YU WATANABE, CHIE WATANABE, MEGUMI XU, ZIXIN

YAJIMA, HIDEAKI YAMADA, MITSUTOSHI YAMAGUCHI, MASATOSHI YAMAGUCHI, NORIKO YAMAMOTO, GAKU YAMANE, SATOMI YAMASAKI, KAI YAMASHITA, MASAMI YAMOCHI, TAKAYUKI YASUOKA, TOSHIAKI YONEMURA, MASAHITO YOSHIDA, HIROAKI YOSHIDA, TAKASHI YOTSUMOTO, FUSANORI YUMURA, YASUSHI YUSA, HIROKO



Korea BACK, SUNG HOON CHAE, IN SOON CHANG, HYE JIN CHO, JUNGRAN CHO, SEOYOUNG CHO, SIHYUN CHOI, BUM CHAE CHOI, EUNA CHOI, YOUNG SIK CHOO, SUNG PIL CHUNG, NANUM HONG, YEON HEE HWANG, KYUNG JOO JANG. JIEUN JEONG, HYE GYEONG JOO, JONG KIL JUNG, HAEUN JUNG, HYE JI KANG, SOKBOM KIM, JEONG SOOK KIM, JI HYANG KIM, JUHEE KIM, MIN KYUNG

SFP SFP S

The 8th World Congress of the International Society for Fertility Preservation



As of November 1st, 2024

KIM, MIRAN KIM, SUNG EUN KIM, YOUJIN KIM, YOUNG MEE KO, JIEUN LEE, BORA LEE, DONG-YUN LEE, INHA LEE, JAE HOON LEE, JANGMI LEE, JUNG RYEOL MALABANAN, CHARISE MAE MIN, HYEWON PARK, HYEMIN PARK, HYO YOUNG PARK, HYUN-TAE PARK, JONGCHAN ROH, HYUN SOOK RYU, KI-JIN SHIN, JUNGWOO SUH, CHANG SUK WOO, CHAEEUN YANG, HEESEON YI, KYONG WOOK YOO, JUNGYOUNG YOON, HYE KYUNG YOON, JEONGMI YOON, YEEUN YU, EUN HEE



Malaysia ABDUL HAMID, FAZILAH ABDUL KADIR, ABDUL KARIM ABDUL WAHAB, ANA VETRIANA ABDUL WAHAB, AZANTEE YAZMIE BT ABDULLAH, NURSHAIREEN CHUE ABU, MUHAMMAD AZRAI AHMAD, MOHD FAIZAL ALI, ANIZAH BIN MOHD ARIS, S MUHAMMAD SHAMSIR CHEONG, SIEW YING

JERIP, R ABIGAIL KHAIRUDDIN, D NURUL KHAIRIYAH LEE, POH CHING LIM, LI CEN MOHD ABAS, MOHD NORAZAM SIKH IBRAHIM, SHARIFAH ADIBAH TAN, KEH YEE YANG MOHSIN, WAN SYAHIRAH YUNG, SHIN CHYI



Nigeria AJAYI, ABAYOMI OBASA-GBADEBO, R ADEOLA



Philippines ABAT, G MARINELLA AGNES ACOSTA, A KAREN ADVIENTO, W CORAZON AGUALADA, M ZARAH CHARISSA BASE, V JEAN ERIKA CHIOMBON, M JULITA DE CHAVEZ-NUEVA, E MARIA DELINA DIONISIO, J MAHARICA IGUALADA, R ARBY JANE MADAYAG, M ALMA MANALO, EILEEN MENDIOLA, B RUDIE FREDERICK NOVERO, M VIRGILIO OÑATE, L HELEN PARCON, G CYNTHIA PEPITO, M SHERYL LYN PUA, B JACQUELINE PUNAY, M MARILEN SIMBAJON, R ROSCARLA SUMUGAT, D GERALYN TANANGONAN, G GLADYS YU, N ELISA



Romania ENACHE, L CARMEN



Russia KARIMOVA, M ALIYA KORABLEVA, NADEZHDA OSEPAISHVILI, MAKA



Serbia MILENKOVIC, MILAN STEFANOVIC, ALEKSANDAR



Singapore Chieng, Roland Nair, Suresh To, Chiou Fen Carine



Sri Lanka HEENNILAME, RATNAYAKE WIJETHUNGA, P HELARUWAN

SFP2024 FERRING

The 8th World Congress of the International Society for Fertility Preservation



As of November 1st, 2024



Sweden AKOURI, RANDA NILSSON, HANNA RODRIGUEZ-WALLBERG, KENNY



Switzerland STILLER, RUTH STUTE, PETRA VON WOLFF, MICHAEL XIE, MIN



Taiwan

CHANG, CHIA-WEI CHEN, CHI-HUANG HOU, JUNG HSIU HSUEH, Y ETHEL HUANG, CHU CHUN HUANG, HSUAN-WEI HUANG, YU-SHIUAN LAN, KUO-CHUNG LEE, CHUN-I LEE, Y WILLIAM LIU, SHANGMIN LUONG, THI-MY-TRANG RUAN, SIOU-YING SU, YUTING TSAI, C YUNGCHIEH TZENG, CHII RUEY WANG, TZU YA WANG, YIPEI WEN, JEN-YU YAO, YI-LIN



Thailand KRITSERNVONG, DHAWINEE KRUTSAWAD, WEENA

KROTSAWAD, WEENA MINGSUTTIPORN, KINGKAEW MUSIGAVONG, OLARIK SANTAMONKUNROT, PORNCHANIT SIRAYAPIWAT, PORNTIP THUWANUT, PAWEENA



Turkey Oktem, ozgur Yildiz, sule



Uganda KAYIIRA, ANTHONY



United Kingdom ILIC, DUSKO KOPEIKA, JULIA KUSCU, NILAY SEMPLE, MAXINE TSONIS, ORESTIS WALLACE, HAMISH WILLIAMS, A SUZANNAH YASMIN, EPHIA



USA **BEHNKE, J ERICA** DETTI, LAURA FALCONE, TOMMASO JAWOREK FRIAS, OLIVIA JORDAN, LARISA KIM. SAMUEL LARONDA, MONICA MAN, LIMOR MUELLER, JENNIFER OKTAY, KUTLUK ORWIG, KYLE PATRIZIO, PASQUALE PEREZ, OSCAR ROSENWAKS, ZEV SCHATTMAN, L GLENN SILBER, SHERMAN TING, ALISON WOODARD, L TERRI ZHAO, YULIAN



Viet Nam Chau, UY BANG HO, M TUONG LE XUAN, LINH LE, ANH LE, KHAC TIEN LE, QUANG LE, T THI MINH CHAU NGUYEN, H DUY NGUYEN, H DUY NGUYEN, TAT NGUYEN, T DAT NGUYEN, THU YEN THI TRAN, CAM VO, T NHAN